,Variant,Chemical,Notes,Sentence,Alleles
0,HLA_DRB1_1501,glatiramer acetate (PA449760),Significant only when also combined with rs180049 allele A. Risk of not responding to the drug was significantly increased in individuals carrying this allele combination. This risk was further increased in individuals with the HLA-DRB1*15-rs1800469 A-rs333 del allele combination and HLA-DRB1*15-rs1800469 A-rs333 del-rs1012335 G allele combination.,HLA-DRB1 *15:01:01:01 is associated with decreased response to glatiramer acetate in people with Multiple Sclerosis.,*15:01:01:01
1,HLA_C_0602,ustekinumab (PA166048654),"After 4 weeks of treatment, 35.7% of patients who carried the HLA-C*06:02 allele responded to treatment with ustekinumab (i.e. a 75% reduction in The Psoriasis Area and Severity Index (PASI) score from baseline), while only 4.3% of those who did not carry the allele responded. At 12 weeks, the percentages were 96.4% and 65.2%. At 28 weeks the percentages were 96.3% and 72.7%. At 40 weeks the percentages were 100% and 73.7%. Ustekinumab was administered at weeks 0 and 4, and every 12 weeks thereafter. The authors analyze and then note that this association is not due to PASI score at baseline or whether the patient had an early onset of psoriasis.",HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.,*06:02:01:01
2,HLA_C_0602,ustekinumab (PA166048654),"After 12 weeks of treatment, 85.7% of patients who carried the HLA-C*06:02 allele responded to treatment with ustekinumab (i.e. a 90% reduction in The Psoriasis Area and Severity Index (PASI) score from baseline), while only 56.5% of those who did not carry the allele responded. At 40 weeks, the percentages were 92.3% and 57.9%. Ustekinumab was administered at weeks 0 and 4, and every 12 weeks thereafter. The authors analyze and then note that this association is not due to PASI score at baseline or whether the patient had an early onset of psoriasis.",HLA-C *06:02:01:01 is associated with increased response to ustekinumab in people with Psoriasis.,*06:02:01:01
3,HLA_B_4402,"interferon alfa-2a, recombinant (PA164779048),""ribavirin (PA451241)""",Patients were described as being treated with interferon-alpha. The presence of an HLA-B*44 allele is associated with an increased likelihood of sustained response to ribavirin and interferon-alpha therapy. This annotation was completed on HLA-B*44:02:01:01 because this was the first *44 allele discovered. This result was NOT significant in those receiving interferon-alpha alone (n = 143).,"HLA-B *44:02:01:01 is associated with increased response to interferon alfa-2a, recombinant and ribavirin in people with Hepatitis C.",*44:02:01:01
4,HLA_A_0101,"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)""","The HLA-A*01 allele was associated with an increased likelihood of sustained virological response, defined as normalization of liver enzymes and negative hepatitis C viral RNA PCR at the end of therapy and for six months following cessation of treatment.","HLA-A *01:01:01:01 is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.",*01:01:01:01
5,HLA_B_3801,"peginterferon alfa-2a (PA164749390),""peginterferon alfa-2b (PA164784024)"",""ribavirin (PA451241)""",Presence of the HLA-B*38 allele was associated with an increased likelihood of non-response to therapy. Non-response was defined as a failure to attain a negative hepatitis C viral RNA at week 24 from the start of treatment or a decline in hepatitis C viral RNA of >= 2 log10 IU/mL at week 12 of treatment.,"HLA-B *38:01:01 is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C.",*38:01:01
6,HLA_B_5801,allopurinol (PA448320),"Association refers to T cell response. In vitro assays measured upregulation of CD107a on CD8 T cells in cultures of T cell lines (TCLs) generated from lymphocytes from allopurinol-naive individuals with a HLA-B*58:01 (n=7) positive or negative (n=7) genotype. Allopurinol or oxypurinol (an active metabolite of allopurinol)-specific TCLs were generated by incubating lymphocytes with different concentrations of drug (1, 10 or 100 ug/mL). Using 100ug/mL of drug, TCLs could be generated from 7/7 HLA-B*58:01+ donors, but only 1/7 HLA-B*58:01- donors. Authors state that this indicates high drug concentrations and the HLA-B*58:01 work synergistically to induce allopurinol/oxypurinol TCLs. Allopurinol-specific TCLs only recognized allopurinol, and oxypurinol-specific TCLs only recognized oxypurinol. One oxypurinol-sepcific TCL from a HLA-B*58:01 donor was able to recognize xanthine.",HLA-B *58:01 is associated with response to allopurinol.,*58:01
7,HLA_B_5801,allopurinol (PA448320),"required to induce a CD8+ T cell response compared to HLA-B*58:01 negative samples (EC50 was significantly lower in HLA-B*58:01+ cell cultures). In vitro assays measured upregulation of CD107a on CD8 T cells in cultures of T cell lines (TCLs) generated from lymphocytes from allopurinol-naive individuals with a HLA-B*58:01 (n=7) positive or negative (n=7) genotype. Allopurinol or oxypurinol (an active metabolite of allopurinol)-specific TCLs were generated by incubating lymphocytes with different concentrations of drug (1, 10 or 100 ug/mL).",HLA-B *58:01 is associated with decreased concentrations of allopurinol.,*58:01
8,HLA_DRB1_0401,"adalimumab (PA10004),""etanercept (PA449515)"",""infliximab (PA452639)"",""Tumor necrosis factor alpha (TNF-alpha) inhibitors (PA164713366)""","Valine at position 11 (VKA haplotype is *04:01) was associated with better EULAR response to TNF inhibitor therapy (OR, 1.14 [95% CI, 1.01-1.30], P=0.04) as compared to HLA-DRB1 *15:01 + *15:02.","HLA-DRB1 *04:01:01 + *04:01:02 + *04:01:03 + *04:01:04 + *04:01:05 + *04:01:06 + *04:01:07 + *04:01:08 are associated with increased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to HLA-DRB1 *15:01:01:01 + *15:02:01.",*04:01:01 + *04:01:02 + *04:01:03 + *04:01:04 + *04:01:05 + *04:01:06 + *04:01:07 + *04:01:08
9,HLA_B_4001,"lamivudine (PA450163),""nevirapine (PA450616)"",""stavudine (PA451494)""","HLA-B*40:01 was a significant predictor of regimen modification due to treatment failure, with presence of the *40:01 allele leading to a decreased risk of regimen modification due to treatment failure.","HLA-B *40:01:01 is associated with response to lamivudine, nevirapine and stavudine in people with HIV.",*40:01:01
10,HLA_A_3303,allopurinol (PA448320),,"HLA-A *33:03 is associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with allopurinol in people with Drug Hypersensitivity.",*33:03
11,HLA_C_0401,nevirapine (PA450616),"Nevirapine hypersensitivity consisted of a fever in combination with a rash and/or hepatitis, and/or eosinophilia. Note that the paper specified the association for C*04, so *04:01 may not be the associated allele. *04 was only associated with nevirapine hypersensitivity with rash.",HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*04:01:01:01
12,HLA_C_0801,nevirapine (PA450616),"Nevirapine hypersensitivity consisted of a fever in combination with a rash and/or hepatitis, and/or eosinophilia. Note that the paper specified the association for C*08, so *08:01 may not be the associated allele. *08 was only associated with multisystemic nevirapine hypersensitivity.",HLA-C *08:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*08:01:01
13,HLA_C_0302,allopurinol (PA448320),,"HLA-C *03:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*03:02
14,HLA_B_5801,allopurinol (PA448320),"P-value was no longer significant after correction due to multiple testing and small sample size, however analysis of HLA-B*58:01-DRB1*13:02 haplotype was significant after correction for the number of comparisons.","HLA-B *58:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*58:01
15,HLA_C_0801,allopurinol (PA448320),,HLA-C *08:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.,*08:01
16,HLA_DRB1_0101,nevirapine (PA450616),"Nevirapine hypersensitivity consisted of a fever in combination with a rash and/or hepatitis, and/or eosinophilia. DRB1*01:01 was associated with all nevirapine hypersensitivity types combined (p=0.04, OR= 3.7), but most strongly with hypersensitivity with hepatic symptoms (p=0.02, OR = 4.2).",HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*01:01:01
17,HLA_B_3501,nevirapine (PA450616),"Nevirapine hypersensitivity consisted of a fever in combination with a rash and/or hepatitis, and/or eosinophilia. B*35:01 was associated with all nevirapine hypersensitivity types combined (p=0.01, OR= 5.1), but most strongly with hypersensitivity with a rash (p=0.006, OR = 7.9).",HLA-B *35:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*35:01:01:01
18,HLA_C_0302,allopurinol (PA448320),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=12) and toxic epidermal necrolysis (TEN; n=6). The allele frequency of *03:02 was 27.8% in those with allopurinol-induced SJS or TEN, compared to 0% in healthy population controls. Bonferroni-corrected p-value set at <5.62 x 10^-8.",HLA-C *03:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:02:01
19,HLA_A_3303,allopurinol (PA448320),"Not significant using Bonferroni-corrected p-value of <5.62 x 10^-8. Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=12) and toxic epidermal necrolysis (TEN; n=6). The *33:03 allele frequency was 22.2% in patients with allopurinol-induced SJS or TEN, and 7.9% in healthy population controls.",HLA-A *33:03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*33:03:01
20,HLA_B_5801,allopurinol (PA448320),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=12) and toxic epidermal necrolysis (TEN; n=6). The allele frequency of *58:01 was 27.8% in those with allopurinol-induced SJS or TEN, compared to 0.6% in healthy population controls. Bonferroni-corrected p-value set at <5.62 x 10^-8.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
21,HLA_DRB1_0102,nevirapine (PA450616),"Patients with the *01:02 allele showed a significantly greater risk for experiencing nevirapine-induced hepatotoxicity, as compared to those without the allele.",HLA-DRB1 *01:02:01 is associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV.,*01:02:01
22,HLA_B_5801,nevirapine (PA450616),"Patients with the *58:01 allele showed a significantly greater risk for experiencing nevirapine-induced hepatotoxicity, as compared to those without the allele.",HLA-B *58:01 is associated with increased risk of Toxic liver disease when treated with nevirapine in people with HIV.,*58:01
23,HLA_B_1510,nevirapine (PA450616),"Patients with the *15:10 allele showed a significantly lower risk for experiencing nevirapine-induced hepatotoxicity, as compared to those without the allele.",HLA-B *15:10:01 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV.,*15:10:01
24,HLA_B_5802,nevirapine (PA450616),"Patients with the *58:02 allele showed a significantly lower risk for experiencing nevirapine-induced hepatotoxicity, as compared to those without the allele.",HLA-B *58:02 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV.,*58:02
25,HLA_C_0210,nevirapine (PA450616),"Patients with the *02:10 allele showed a significantly lower risk for experiencing nevirapine-induced hepatotoxicity, as compared to those without the allele.",HLA-C *02:10 is associated with decreased risk of Toxic liver disease when treated with nevirapine in people with HIV.,*02:10
26,HLA_B_1502,oxcarbazepine (PA450732),No significant difference in the frequencies of the *15:02 was seen between patients who developed oxcarbazepine-induced maculopapular eruption and oxcarbazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.,HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*15:02:01
27,HLA_B_1302,oxcarbazepine (PA450732),"The frequency of the *13:02 allele was significantly higher in those with oxcarbazepine-induced maculopapular eruption (MPE) as compared to healthy population controls. However, no significant association was seen when comparing those MPE against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *13:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*13:02:01
28,HLA_B_1519,oxcarbazepine (PA450732),"The frequency of the *15:19 allele was significantly higher in those with oxcarbazepine-induced maculopapular eruption (MPE) as compared to healthy population controls. However, no significant association was seen when comparing those MPE against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *15:19 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*15:19
29,HLA_B_1527,oxcarbazepine (PA450732),"The frequency of the *15:27 allele was significantly higher in those with oxcarbazepine-induced maculopapular eruption (MPE) as compared to healthy population controls. However, no significant association was seen when comparing those MPE against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *15:27:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*15:27:01
30,HLA_B_2709,oxcarbazepine (PA450732),"The frequency of the *27:09 allele was significantly higher in those with oxcarbazepine-induced maculopapular eruption (MPE) as compared to healthy population controls. However, no significant association was seen when comparing those MPE against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *27:09 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*27:09
31,HLA_A_0301,phenytoin (PA450947),Risk of increased risk of cutaneous adverse reactions. Allele was reported as HLA-A*3101.,HLA-A *03:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.,*03:01:01:01
32,HLA_A_0301,lamotrigine (PA450164),Risk of increased risk of cutaneous adverse reactions. Allele was reported as HLA-A*3101.,HLA-A *03:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*03:01:01:01
33,HLA_B_5701,abacavir (PA448004),,HLA-B *57:01:01 is associated with increased likelihood of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
34,HLA_B_5801,allopurinol (PA448320),"Association reported for the HLA-B*5801 allele. Sensitivity = 92.0%, Specificity = 89.5%, positive predictive value = 2.06% and negative predictive value = 99.98% (the latter two values were calculated on the assumption that prevalence of allopurinol-induced SCARs is 0.24%). N=22/26 patients with SCARs carried HLA-B*5801-C*0302-A*3303 and n=24/26 carried HLA-B*5801-C*0302.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
35,HLA_DQB1_0303,abacavir (PA448004),"Frequency of combined HLA-DR7 (HLA-DRB1*0701), HLA-DQ3 (HLA-DQB1*0303) alleles was significantly higher in abacavir hypersensitive patients compared to tolerant patients. Please note; here we represent *03:03 with *03:03:03.",HLA-DQB1 *03:03:03 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.,*03:03:03
36,HLA_B_4001,carbamazepine (PA448785),,HLA-B *40:01:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.,*40:01:01
37,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*15:02:01
38,HLA_B_5701,abacavir (PA448004),Frequency of HLA-B*5701 was significantly higher in abacavir hypersensitive patients compared to tolerant patients. Please note; here we represent *57:01 with *57:01:01.,HLA-B *57:01:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.,*57:01:01
39,HLA_A_3101,carbamazepine (PA448785),HLA-A*3101 is significantly associated with all phenotypes of CBZ hypersensitivity in multiple ethnicities.,HLA-A *31:01:02 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.,*31:01:02
40,HLA_B_5801,allopurinol (PA448320),or hyperuricemia. Risk of cutaneous adverse drug reactions (mild or severe).,"HLA-B *58:01/*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.",*58:01/*58:01
41,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.,*15:02:01
42,HLA_B_5801,allopurinol (PA448320),"Please note: the association reported was with HLA-B*58 (allele subtype was not defined). Authors stated ""Korea is one of the countries with a high frequency of HLA-B*5801 which is the only subtype of HLA-B58 in the Korean population."" Freq in healthy controls given as 12.2%. *Unclear if p-values are corrected for multiple testing.*","HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.",*58:01
43,HLA_B_1502,phenytoin (PA450947),,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.,*15:02:01
44,HLA_DRB1_0701,abacavir (PA448004),"Frequency of combined HLA-DR7 (HLA-DRB1*0701), HLA-DQ3 (HLA-DQB1*0303) alleles was significantly higher in abacavir hypersensitive patients compared to tolerant patients. Please note; here we represent *07:01 with *07:01:01.",HLA-DRB1 *07:01:01:01 is associated with increased risk of hypersensitivity when treated with abacavir in people with HIV Infections.,*07:01:01:01
45,HLA_B_5801,allopurinol (PA448320),"Authors stated that ""The positive predictive value of the HLA-B*5801 allele was 1.52% with 100% negative predictive value"" (assuming that the prevalence of SJS/TEN in the Thai population si sthe same as for the Taiwanese population). Not stated whether the p-value was corrected for multiple testing.","HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*58:01
46,HLA_B_5801,allopurinol (PA448320),"The allele frequency in patients who developed SJS/TEN was compared against the allele frequency in a sample of the Japanese population (n=493), not allopurinol-tolerant patients. The HLA-B*5801 allele was also found in a patient with SJS/TEN who was not treated with allopurinol. Whether correction for multiple comparisons was applied was not stated.","HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol.",*58:01
47,HLA_B_1502,carbamazepine (PA448785),"The only CBZ-SJS patient who did not have the B*1502 allele, had instead, another HLA-B15 allele: HLA-B*1558.",HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.,*15:02:01
48,HLA_B_5801,allopurinol (PA448320),,HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.,*58:01
49,HLA_B_5801,allopurinol (PA448320),or hyperuricemia. Risk of cutaneous adverse drug reactions (mild or severe). Chronic renal insufficiency was also associated with increased risk of SCAR.,"HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Arthritis, Gouty.",*58:01
50,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*15:02:01
51,HLA_B_1502,"carbamazepine (PA448785),""phenytoin (PA450947)""",,HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine or phenytoin in people with Epilepsy.,*15:02:01
52,HLA_B_1502,carbamazepine (PA448785),in a European population. The 4 patients who were positive for HLA-B*1502 turned out to have Asian ancestry.,HLA-B *15:02:01 is not associated with Stevens-Johnson Syndrome when treated with carbamazepine.,*15:02:01
53,HLA_B_5701,abacavir (PA448004),As compared to those without the HLA-B*57:01:01 allele (referred to as *57:01 in the paper).,HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
54,HLA_B_5801,allopurinol (PA448320),"Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were also significantly associated with increased risk, but were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
55,HLA_B_5701,abacavir (PA448004),This study demonstrated that prospective screening was highly effective at preventing drug hypersensitivity to abacavir.,HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
56,HLA_DQA1_0102,Drugs For Treatment Of Tuberculosis (PA164712708),"The absence of the HLA-DQA1*0102 allele was associated with increased risk, with an allele frequency higher in patients who did not develop hepatotoxicity than cases.",HLA-DQA1 *01:02:01:01 is associated with decreased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.,*01:02:01:01
57,HLA_B_1502,"carbamazepine (PA448785),""oxcarbazepine (PA450732)"",""phenobarbital (PA450911)""","Children with aromatic antiepileptic-induced Stevens-Johnson Syndrome had a higher frequency of the *15:02 allele, as compared to antiepileptic-tolerant controls and healthy population controls.","HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.",*15:02:01
58,HLA_B_1502,oxcarbazepine (PA450732),,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with oxcarbazepine in Epilepsy.,*15:02:01
59,HLA_DRB1_1602,phenytoin (PA450947),,HLA-DRB1 *16:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*16:02:01
60,HLA_B_1502,"carbamazepine (PA448785),""phenytoin (PA450947)""",,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.,*15:02:01
61,HLA_B_1502,"antiepileptics (PA143485705),""carbamazepine (PA448785)""",,HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.,*15:02:01
62,HLA_B_1502,lamotrigine (PA450164),,HLA-B *15:02:01 is not associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in Epilepsy.,*15:02:01
63,HLA_B_1301,phenytoin (PA450947),,HLA-B *13:01:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*13:01:01
64,HLA_B_1501,phenytoin (PA450947),"IMPORTANT NOTE: This is a case report. There are 2 cases in this paper, this is the first case who has HLA-B*1501/B*5401 genotype.",HLA-B *15:01:01:01 + *54:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*15:01:01:01 + *54:01:01
65,HLA_B_1502,"antiepileptics (PA143485705),""carbamazepine (PA448785)""",,HLA-B *15:02:01 is not associated with increased risk of maculopapular exanthema when treated with antiepileptics or carbamazepine in Epilepsy.,*15:02:01
66,HLA_B_3701,phenytoin (PA450947),"IMPORTANT NOTE: This study have two cases only. Both cases do not have HLA-B*15:02 allele. This is the second case, who has HLA-B*3701/B*4601 allele",HLA-B *46:01:01 + *37:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*46:01:01 + *37:01:01
67,HLA_B_1502,phenytoin (PA450947),,HLA-B *15:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*15:02:01
68,HLA_B_1502,phenytoin (PA450947),"IMPORTANT NOTE: This is a case report. There are 2 cases in this paper, this is the second case who has HLA-B*1502/B*4601 genotype.",HLA-B *15:02:01 + *46:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*15:02:01 + *46:01:01
69,HLA_B_4601,phenytoin (PA450947),"IMPORTANT NOTE: This study have two cases only. Both cases do not have HLA-B*15:02 allele. This is the first case, who has HLA-B*4601/B*5102",HLA-B *46:01:01 + *51:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*46:01:01 + *51:02:01
70,HLA_C_0801,phenytoin (PA450947),,HLA-C *08:01:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.,*08:01:01
71,HLA_DQB1_0201,Drugs For Treatment Of Tuberculosis (PA164712708),,HLA-DQB1 *02:01:01 is associated with increased likelihood of Toxic liver disease when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.,*02:01:01
72,HLA_A_3101,carbamazepine (PA448785),,HLA-A *31:01:02 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.,*31:01:02
73,HLA_A_3101,carbamazepine (PA448785),,HLA-A *31:01:02 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.,*31:01:02
74,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.,*15:02:01
75,HLA_A_3101,carbamazepine (PA448785),,HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.,*31:01:02
76,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.,*15:02:01
77,HLA_B_1502,carbamazepine (PA448785),,HLA-B *15:02:01 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.,*15:02:01
78,HLA_B_1502,carbamazepine (PA448785),Controls were patients tolerant to carbamazepine after taking it for at least 3 months without developing a skin rash.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.",*15:02:01
79,HLA_B_5801,allopurinol (PA448320),"Case reports. Case 1: male with 8-day history of fever and diffuse erythema all over the body. Patient had been on allopurinol and benzbromarone, as well as vildagliptin and calcitriol. Case 2: male with 10-day history of fever and generalized itching and erythema. Allopruinol was started 1 month previously. Patient also taking amlodipine, valsartan and ""some Chinese medicines"". Both patients were positive for HLA-B*58:01.","HLA-B *58:01 is associated with Dermatitis, Exfoliative when treated with allopurinol.",*58:01
80,HLA_DRB1_0410,phenobarbital (PA450911),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *04:10.,HLA-DRB1 *04:10:01 is not associated with Stevens-Johnson Syndrome when treated with phenobarbital.,*04:10:01
81,HLA_B_1502,valproic acid (PA451846),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 3 cases were compared against 15 controls; cases developed SJS/TEN on valproic acid, controls did not. p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.",HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with valproic acid in people with Epilepsy.,*15:02:01
82,HLA_A_2420,phenobarbital (PA450911),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction.,HLA-A *24:20 is not associated with Stevens-Johnson Syndrome when treated with phenobarbital.,*24:20
83,HLA_A_3101,carbamazepine (PA448785),cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions),HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
84,HLA_B_1502,phenobarbital (PA450911),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 2 cases were compared against 10 controls; cases developed SJS/TEN on phenobarbital, controls did not. p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.",HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenobarbital in people with Epilepsy.,*15:02:01
85,HLA_A_2402,carbamazepine (PA448785),meta-analysis on the basis of bullous cADRs; Meta-analysis found a significant association of HLA-A*2402 as a protective factor in patients showing only bullous cADRs.,HLA-A *24:02:01:01 is associated with decreased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.,*24:02:01:01
86,HLA_B_4001,carbamazepine (PA448785),"HLA-B*4001 was observed to be protective, with a significant over-representation in CBZ-tolerant patients. cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions)",HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*40:01:01
87,HLA_DRB1_0101,lumiracoxib (PA164769031),and elevated liver enzymes. This is for HLA-DQB1*1501 allele.,HLA-DRB1 *15:01:01:01 is associated with increased risk of Toxic liver disease when treated with lumiracoxib as compared to HLA-DRB1 *01:01:01.,*15:01:01:01
88,HLA_A_3301,allopurinol (PA448320),"3 cases reported. HLA typing showed the first case had HLA-A31, A33, B51 and B58, the second had HLA-A31, A33, B39 and B58, the third had HLA-A24, A33, B52 and B58 (all had A33 and B58). Please note; here we represent HLA-A33 with the allele *33:01:01.",HLA-A *33:01:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.,*33:01:01
89,HLA_B_5801,allopurinol (PA448320),"3 cases reported. HLA typing showed the first case had HLA-A31, A33, B51 and B58, the second had HLA-A31, A33, B39 and B58, the third had HLA-A24, A33, B52 and B58 (all had A33 and B58). Please note; here we represent HLA-B58 with the *58:01 allele.",HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol in men.,*58:01
90,HLA_B_1511,carbamazepine (PA448785),Increased risk of carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions. Meta-analysis on the basis of bullous cADRs; over-representation of HLA-B*1511 in patients showing bullous cADRs.,HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.,*15:11:01
91,HLA_B_1502,phenytoin (PA450947),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This was a meta-analysis, which included two case-control studies, where 41 cases were compared against 188 controls; cases developed SJS/TEN on phenytoin, controls did not.",HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.,*15:02:01
92,HLA_A_0207,zonisamide (PA451978),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The allele used here represents *02:07.,HLA-A *02:07:01 is associated with Stevens-Johnson Syndrome when treated with zonisamide.,*02:07:01
93,HLA_B_5101,phenytoin (PA450947),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *51:01.,HLA-B *51:01:01 is not associated with Stevens-Johnson Syndrome when treated with phenytoin.,*51:01:01
94,HLA_B_5801,allopurinol (PA448320),A case report of a male who developed DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) 1 month after allopurinol treatment started. He was found to carry the HLA-B*58:01 allele (not clear whether testing for other alleles was done).,HLA-B *58:01 is associated with drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in men with Hyperuricemia.,*58:01
95,HLA_DQB1_0602,lumiracoxib (PA164769031),and elevated liver enzymes. This is for HLA-DQB1*0602 allele.,HLA-DQB1 *06:02:01 is associated with increased risk of Toxic liver disease when treated with lumiracoxib.,*06:02:01
96,HLA_B_5801,allopurinol (PA448320),"A case study of a man who developed SJS after being prescribed allopurinol. His brother is allopurinol-tolerant. Both had gout and essential hypertension. Typing was carried out for him and his family members. He had the HLA-B*58:01 allele, and his brother did not.",HLA-B *58:01 is associated with Stevens-Johnson Syndrome when treated with allopurinol in men with Gout.,*58:01
97,HLA_B_1502,carbamazepine (PA448785),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele have a greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 26 cases were compared against 135 controls; cases developed SJS/TEN on carbamazepine, controls did not. p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.",HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*15:02:01
98,HLA_B_4001,carbamazepine (PA448785),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*40:01 allele have a decreased risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 26 cases were compared against 135 controls; cases developed SJS/TEN on carbamazepine, controls did not.",HLA-B *40:01:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*40:01:01
99,HLA_B_5801,allopurinol (PA448320),SCARs included DRESS and SJS/TEN. Maculopapular eruption (MPE) was not associated - only one case/6 carried the HLA-B*5801 allele. Correction for multiple testing was not stated.,HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Hyperuricemia.,*58:01
100,HLA_B_5801,allopurinol (PA448320),A case report of a girl being treated with an anti-TB regimen for tuberculosis infection who developed asymptomatic hyperuricemia. She was treated with allopurinol and subsequently developed TEN. A test showed she carried to HLA-B*5801 allele.,"HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic when treated with allopurinol in children with Hyperuricemia.",*58:01
101,HLA_B_1502,carbamazepine (PA448785),Increased risk for carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions. Meta-analysis on the basis of bullous cADRs,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.,*15:02:01
102,HLA_B_5801,allopurinol (PA448320),"Only one patient in the cases group did not have HLA-B*5801...this patient exhibited the less severe ADR of erythema multiforme major (EMM), and when this patient was excluded the OR was even higher (see study parameters below). Only tested for the HLA-B*58:01 allele. Chronic renal insufficiency and female gender was also significantly associated with increased risk of allopurinol-induced SCAR.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
103,HLA_B_5801,allopurinol (PA448320),The HLA-B*58:01 allele was found in all patients tested for the allele. The allele frequency of HLA-B*58:01 in patients who experienced allopurinol-induced SJS/TEN was compared against the allele frequency in Europeans (0.015) - the odds ratio and p-value provided represent these statistics. Unclear whether other alleles were tested for.,"HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*58:01
104,HLA_B_5801,allopurinol (PA448320),"The HLA-B*5801 allele was found in 5/6 patients with Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TEN), 1/5 cases with drug reaction with eosinophilia and systemic symptoms/ drug-induced hypersensivity syndrome (DRESS/DIHS), and 0/12 patients with MPE. Genotyped at the HLA-B locus - not clear if any other alleles were found.",HLA-B *58:01 is associated with Drug Hypersensitivity when treated with allopurinol.,*58:01
105,HLA_B_5801,antiepileptics (PA143485705),"Antiepileptics included gabapentin, lamotrigine, levetiracetam, phenobarbital, phenytoin and valproic acid. Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*58:01 allele have a decreased risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 28 cases were compared against 140 controls; cases developed SJS/TEN on these drugs, controls did not.",HLA-B *58:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.,*58:01
106,HLA_B_1502,lamotrigine (PA450164),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This was a meta-analysis, which included four case-control studies, where 17 cases were compared against 146 controls; cases developed SJS/TEN on lamotrigine, controls did not.",HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.,*15:02:01
107,HLA_B_1502,carbamazepine (PA448785),cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions),HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
108,HLA_B_1502,lamotrigine (PA450164),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 6 cases were compared against 30 controls; cases developed SJS/TEN on lamotrigine, controls did not. p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction. However, please note that this paper also conducted a meta-analysis which included this study plus another three studies, and found significant results for lamotrigine-induced SJS/TEN in HLA-B *15:02 carriers.",HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with lamotrigine in people with Epilepsy.,*15:02:01
109,HLA_B_5801,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. Genotyping/ typing method: PCR-rSSO and PCR-SBT methods. High resolultion confirmed it was the HLA-B*58:01 allele. Whether correction for multiple testing was carried out was not stated.",HLA-B *58:01 is associated with increased risk of erythema exudativum multiforme or Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*58:01
110,HLA_DQA1_0101,lumiracoxib (PA164769031),and elevated liver enzymes. This is for HLA-DQA1*0102 allele.,HLA-DQA1 *01:02:01:01 is associated with increased risk of Toxic liver disease when treated with lumiracoxib as compared to HLA-DQA1 *01:01:01.,*01:02:01:01
111,HLA_B_1301,dapsone (PA449211),The association was found with development of the dapsone hypersensitivity syndrome. Please note that this study found a gene-dose effect for the *13:01 allele and development of dapsone hypersensitivity syndrome.,HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.,*13:01:01
112,HLA_B_5801,allopurinol (PA448320),"Phenotype: Stevens-Johnson Syndrome/Epidermal Necrolysis, Toxic.",HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with allopurinol.,*58:01
113,HLA_B_5101,phenobarbital (PA450911),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The allele used here represents *51:01.,HLA-B *51:01:01 is associated with Stevens-Johnson Syndrome when treated with phenobarbital.,*51:01:01
114,HLA_B_4601,zonisamide (PA451978),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *46:01.,HLA-B *46:01:01 is not associated with Stevens-Johnson Syndrome when treated with zonisamide.,*46:01:01
115,HLA_DRB1_0803,zonisamide (PA451978),Phenotype: Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *08:03.,HLA-DRB1 *08:03:02 is not associated with Stevens-Johnson Syndrome when treated with zonisamide.,*08:03:02
116,HLA_B_1502,phenytoin (PA450947),"Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele, after p-value adjustment for multiple comparisons using Bonferroni's correction (p < 0.01 was considered significant). This study was done in a case-control format, where 15 cases were compared against 75 controls; cases developed SJS/TEN on phenytoin, controls did not. However, please note that this paper also conducted a meta-analysis which included this study plus another study, and found significant results for phenytoin-induced SJS/TEN in HLA-B *15:02 carriers.",HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.,*15:02:01
117,HLA_B_5701,abacavir (PA448004),The *57:01 allele was absent in the entire cohort - both in the six abacavir hypersensitivity cases and in the 241 abacavir tolerant participants. A *57:01 allele frequency of 3.1% has been reported in a different Ugandan population.,HLA-B *57:01:01 is not associated with risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
118,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
119,HLA_B_1502,oxcarbazepine (PA450732),"No significant differences in frequencies of the *15:02 allele were seen between those with oxcarbazepine-induced maculopapular eruption, and oxcarbazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine.,*15:02:01
120,HLA_B_3802,oxcarbazepine (PA450732),"Patients with oxcarbazepine-induced maculopapular eruption had a greater frequency of the *38:02 allele, as compared to healthy population controls. However, no significant difference in frequencies was seen when comparing against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *38:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine.,*38:02:01
121,HLA_A_2407,nevirapine (PA450616),"No significant increase or decrease in risk for nevirapine-induced skin rash was seen in people who carried the HLA-A*24:07 allele. *24:07 was observed in 7.8% of the patients with nevirapine-induced skin rash (case), and 0.7% of nevirapine-tolerant patients (control). p-value corrected using Bonferroni's correction; note that the p-value before correction was significant (p = 3.6 x 10^-3).",HLA-A *24:07 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.,*24:07
122,HLA_A_3101,carbamazepine (PA448785),"Patients with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls or healthy population controls, in both European and Chinese populations.",HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.,*31:01:02
123,HLA_A_3101,carbamazepine (PA448785),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant differences in *31:01 allele frequency were seen between patients with carbamazepine-induced SJS or TEN, and carbamazepine-tolerant patients or healthy population controls, either in a European or Chinese population.",HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
124,HLA_A_3101,carbamazepine (PA448785),"Meta-analysis. Patients with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls in European (3 studies) and Asian (5 studies) populations, and both populations combined (8 studies).",HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.,*31:01:02
125,HLA_A_3101,carbamazepine (PA448785),"Meta-analysis. Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls, in a European population (3 studies) and a European and Asian combined population (8 studies), but NOT in an exclusively Asian population (5 studies).",HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
126,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). European patients with carbamazepine-induced SJS or TEN did not have a significantly different *15:02 allele frequency from carbamazepine-tolerant controls or healthy population controls. However, this result was significant in a Chinese population.",HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
127,HLA_B_3505,nevirapine (PA450616),HLA-B*35:05 was observed in 17.5% (25/143) of the patients with nevirapine-induced skin rash (case) and only 1.1% (2/181) of nevirapine-tolerant patients (control). This association was found to be independent of the severity of the skin rash. Note that the positive history of drug allergies and the number of CD4+ T cells at the beginning of treatment were all also significantly associated with a risk of nevirapine-induced skin rash in logistic regression analysis.,HLA-B *35:05:01 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV.,*35:05:01
128,HLA_B_3802,nevirapine (PA450616),"No significant increase or decrease in risk for nevirapine-induced skin rash was seen in people who carried the HLA-B*38:02 allele. *38:02 was observed in 2% of the patients with nevirapine-induced skin rash (case), and 8.6% of nevirapine-tolerant patients (control). p-value corrected using Bonferroni's correction; note that the p-value before correction was significant (p = 1.8 x 10^-2).",HLA-B *38:02:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.,*38:02:01
129,HLA_C_0401,nevirapine (PA450616),"No significant increase or decrease in risk for nevirapine-induced skin rash was seen in people who carried the HLA-Cw*04:01 allele. *04:01 was observed in 13.3% of the patients with nevirapine-induced skin rash (case), and 2.8% of nevirapine-tolerant patients (control). p-value corrected using Bonferroni's correction; note that the p-value before correction was significant (p = 1.3 x 10^-3).",HLA-C *04:01:01:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.,*04:01:01:01
130,HLA_C_0702,nevirapine (PA450616),"No significant increase or decrease in risk for nevirapine-induced skin rash was seen in people who carried the HLA-Cw*07:02 allele. *07:02 was observed in 10.9% of the patients with nevirapine-induced skin rash (case), and 23.6% of nevirapine-tolerant patients (control). p-value corrected using Bonferroni's correction; note that the p-value before correction was significant (p = 6.7 x 10^-3).",HLA-C *07:02:01:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.,*07:02:01:01
131,HLA_DRB1_1202,nevirapine (PA450616),"No significant increase or decrease in risk for nevirapine-induced skin rash was seen in people who carried the HLA-DRB1*12:02 allele. *12:02 was observed in 10.9% of the patients with nevirapine-induced skin rash (case), and 11.9% of nevirapine-tolerant patients (control). p-value corrected using Bonferroni's correction; note that the p-value before correction was significant (p = 2.4 x 10^-3).",HLA-DRB1 *12:02:01 is not associated with risk of Exanthema when treated with nevirapine in people with HIV.,*12:02:01
132,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Chinese patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls or healthy population controls. This result was NOT significant in a European population.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
133,HLA_B_1502,lamotrigine (PA450164),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant increase in risk for SJS or TEN was seen in patients carrying the *15:02 allele. *15:02 frequency was 1/3 (33.3%) in lamotrigine-induced SJS/TEN patients, 1/21 (4.8%) in lamotrigine-tolerant patients, and 6/71 (8.5%) in healthy volunteers.",HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine.,*15:02:01
134,HLA_B_1502,lamotrigine (PA450164),"No significant increase in risk for maculopapular exanthema (MPE) was seen in patients carrying the *15:02 allele. *15:02 frequency was 2/22 (9.1%) in lamotrigine-induced MPE patients, 1/21 (4.8%) in lamotrigine-tolerant patients, and 6/71 (8.5%) in healthy volunteers.",HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with lamotrigine.,*15:02:01
135,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The HLA-B*15:02 allele was present in 94.1% (32/34) of patients with carbamazepine-induced SJS/TEN, but only in 17.5% (7/40) of carbamazepine-tolerant controls.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.,*15:02:01
136,HLA_C_0303,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (23.5%) or SCARs (29.1%) and carbamazepine-tolerant controls (24%).",HLA-C *03:03:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*03:03:01
137,HLA_C_0304,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (0.0%), HSS (23.5%) or SCARs (16.7%) and carbamazepine-tolerant controls (12%).",HLA-C *03:04:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*03:04:01:01
138,HLA_C_0602,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (0.0%), HSS (23.5%) or SCARs (16.7%) and carbamazepine-tolerant controls (10%).",HLA-C *06:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*06:02:01:01
139,HLA_C_1402,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (16%).",HLA-C *14:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*14:02:01
140,HLA_B_1301,trichloroethylene (PA166115521),"Workers with the *13:01 allele who are exposed to trichloroethylene have an increased risk of hypersensitivity dermatitis, as compared to those without the allele. 83/113 (73.5%) of workers with hypersensitivity dermatitis had the allele, as compared to 13/142 (9.2%) of workers who were tolerant of trichloroethylene. p-value corrected for multiple testing (Bonferroni).",HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene.,*13:01:01
141,HLA_B_4402,trichloroethylene (PA166115521),"Workers with the *44 allele who are exposed to trichloroethylene have an increased risk of hypersensitivity dermatitis, as compared to those without the allele. This results was NOT significant after correction for multiple testing (p>0.05; Bonferroni). 7/113 (6.2%) of workers with hypersensitivity dermatitis had the allele, as compared to 0/142 (0%) of workers who were tolerant of trichloroethylene. The study analyzed HLA-B*44 alleles, and mentioned that this ""included"" *44:02 and *44:03, therefore subjects may have carried other *44 alleles.",HLA-B *44:02:01:01 + *44:03:01 is associated with increased risk of Drug Hypersensitivity when exposed to trichloroethylene.,*44:02:01:01 + *44:03:01
142,HLA_B_0702,carbamazepine (PA448785),"Possession of the *07:02 allele was found to have a protective effect on the development of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n=18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)), as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *07:02:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*07:02:01
143,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *44:02 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *44:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*44:02:01:01
144,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *57:01 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *57:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*57:01:01
145,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *40:01 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*40:01:01
146,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *51:01 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*51:01:01
147,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *15:02 allele was present in 94.1% (16/17) of individuals with carbamazepine-induced SJS/TEN, as compared to 9.5% (2/21) of carbamazepine-tolerant controls, and 9.2% (17/185) of healthy individuals.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
148,HLA_B_1502,carbamazepine (PA448785),"100% of patients with Stevens-Johnson Syndrome carried the *15:02 allele, as compared to none of the carbamazepine-tolerant controls (however, note that two of the tolerant controls were listed only as having HLA-B*15).",HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*15:02:01
149,HLA_B_1502,carbamazepine (PA448785),"36.4% of the patients with a carbamazepine-induced rash carried the *15:02 allele, as compared to none of the carbamazepine-tolerant controls (however, note that two of the tolerant controls were listed only as having HLA-B*15).",HLA-B *15:02:01 is not associated with risk of Exanthema when treated with carbamazepine in people with Epilepsy.,*15:02:01
150,HLA_A_2402,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) or toxic epidermal necrolysis (TEN; n=1). Patients who experienced carbamazepine-induced SJS or TEN had an increased frequency of the *24:02 allele, as compared to carbamazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.",HLA-A *24:02:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*24:02:01:01
151,HLA_A_3101,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). No significant differences in the frequencies of the *31:01 allele were seen between those with carbamazepine-induced SJS or TEN, and carbamazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.",HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
152,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant patients and healthy population controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
153,HLA_B_1511,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:11 allele, as compared to healthy population controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:11:01
154,HLA_B_1502,carbamazepine (PA448785),Severe cutaneous adverse reactions include Stevens-Johnson Syndrome and toxic epidermal necrolysis. Meta-analysis that included 16 studies. Significant results were also seen when considering only Thai patients (2 studies) and only Han Chinese patients (5 studies).,HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
155,HLA_A_3101,carbamazepine (PA448785),"Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). Patients with carbamazepine-induced MPE or DRESS had an increased frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.",HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.,*31:01:02
156,HLA_A_3101,carbamazepine (PA448785),Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant difference in the frequency of the *31:01 allele was seen between those with carbamazepine-induced SJS or TEN and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.,HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
157,HLA_B_5901,methazolamide (PA450413),Case reports. Four cases of Stevens-Johnson syndrome considered to be induced by methazolamide were reported. 3 out of the 4 cases were positive for HLA-B*59.,HLA-B *59:01:01:01 is associated with Stevens-Johnson Syndrome when treated with methazolamide in people with Glaucoma.,*59:01:01:01
158,HLA_B_4804,oxcarbazepine (PA450732),"The frequency of the *48:04 allele was significantly higher in those with oxcarbazepine-induced maculopapular eruption (MPE) as compared to healthy population controls. However, no significant association was seen when comparing those MPE against oxcarbazepine-tolerant controls. Note that p-values not adjusted for multiple comparisons.",HLA-B *48:04 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*48:04
159,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Children who developed carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.,*15:02:01
160,HLA_B_1502,carbamazepine (PA448785),"Hypersensitive skin syndrome (HSS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *15:02 allele was seen between children with carbamazepine-induced HSS and carbamazepine-tolerant controls.",HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine in children.,*15:02:01
161,HLA_B_1502,carbamazepine (PA448785),Minor drug reactions included maculopapular exanthema and urticaria. No significant difference in the frequency of the *15:02 allele was seen between children with carbamazepine-induced minor drug reactions and carbamazepine-tolerant controls.,HLA-B *15:02:01 is not associated with risk of minor drug reactions when treated with carbamazepine in children.,*15:02:01
162,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *15:01 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *15:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*15:01:01:01
163,HLA_B_0801,carbamazepine (PA448785),"No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *27:05 allele, as compared to those with two copies of the most common variant allele, *08:01.",HLA-B *27:05:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.,*27:05:02
164,HLA_B_5701,flucloxacillin (PA164781042),,HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.,*57:01:01
165,HLA_B_5701,flucloxacillin (PA164781042),Replication analysis. Patients were exposed to co-amoxiclav concurrently with flucloxacillin (n=7) or were flucloxacillin drug-induced liver injury cases recruited after the initial analysis (n=16).,HLA-B *57:01:01 is associated with increased risk of drug-induced liver injury when treated with flucloxacillin.,*57:01:01
166,HLA_B_1518,carbamazepine (PA448785),"Note that no p-value was given, only relative risk.",HLA-B *15:18:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*15:18:01
167,HLA_B_5901,carbamazepine (PA448785),"Note that no p-value was given, only relative risk.",HLA-B *59:01:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*59:01:01:01
168,HLA_C_0704,carbamazepine (PA448785),"Note that no p-value was given, only relative risk.",HLA-C *07:04:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.,*07:04:01
169,HLA_C_0102,methazolamide (PA450413),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (n=1) and toxic epidermal necrolysis (n=4). One patient had taken methazolamide previously for 1 day before rash development and had a history of previous sulfonamide antibiotic drug allergy. The *01:02 allele was detected in 5 out of 5 patients who developed methazolamide-induced SJS or TEN, and in 161 out of 485 people in the general Korean population. This allele is closely linked to HLA-B*59:01 by linkage disequilibrium.",HLA-C *01:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.,*01:02:01
170,HLA_A_2402,methazolamide (PA450413),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (n=1) and toxic epidermal necrolysis (n=4). One patient had taken methazolamide previously for 1 day before rash development and had a history of previous sulfonamide antibiotic drug allergy. No significant increase or decrease in the risk of methazolamide-induced SJS or TEN was seen for patients carrying the *24:02 allele, as compared to general population controls. The *24:02 allele was detected in 4 out of 5 patients who developed methazolamide-induced SJS or TEN, and in 188 out of 485 people in the general Korean population. This allele is closely linked to HLA-B*59:01 by linkage disequilibrium.",HLA-A *24:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with methazolamide.,*24:02:01:01
171,HLA_B_5901,methazolamide (PA450413),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (n=1) and toxic epidermal necrolysis (n=4). One patient had taken methazolamide previously for 1 day before rash development and had a history of previous sulfonamide antibiotic drug allergy. The *59:01 allele was detected in 5 out of 5 patients who developed methazolamide-induced SJS or TEN, and in 20 out of 485 people in the general Korean population.",HLA-B *59:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with methazolamide.,*59:01:01:01
172,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=3) and toxic epidermal necrolysis (TEN; n=5). 8/8 patents with carbamazepine-induced SJS or TEN (case) carried the *15:02 allele, as compared to 4/50 carbamazepine-tolerant controls (control) and 6/71 healthy volunteers (control).",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
173,HLA_B_1502,carbamazepine (PA448785),"No significant increase in risk for maculopapular eruption (MPE) was seen for patients carrying the *15:02 allele. 3/28 patients with MPE carried the allele, compared to 4/50 carbamazepine-tolerant controls and 6/71 healthy volunteers.",HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.,*15:02:01
174,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls. Results were also significant when considering only patients with TEN, SJS/TEN overlap, SJS, SJS with 6-9% area of skin detachment, SJS with 2-5% area of skin detachment, and SJS with <= 1% area of skin detachment; refer to paper for p-values and odds ratios. Adjusted p-values using Bonferroni's correction.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
175,HLA_B_4001,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a decreased frequency of the *40:01 allele, as compared to carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.",HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*40:01:01
176,HLA_B_1502,carbamazepine (PA448785),Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *15:02 allele was seen between those with carbamazepine-induced MPE or DRESS and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.,HLA-B *15:02:01 is not associated with risk of Drug Hypersensitivity when treated with carbamazepine.,*15:02:01
177,HLA_B_5101,carbamazepine (PA448785),"Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). Patients with carbamazepine-induced MPE or MPE/DRESS had an increased frequency of the *51:01 allele, as compared to carbamazepine-tolerant controls. However, no significant difference in frequencies was seen when considering patients with DRESS alone. Adjusted p-values using Bonferroni's correction.",HLA-B *51:01:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.,*51:01:01
178,HLA_B_5101,carbamazepine (PA448785),Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant difference in the frequency of the *51:01 allele was seen between those with carbamazepine-induced SJS or TEN and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.,HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*51:01:01
179,HLA_B_4001,carbamazepine (PA448785),Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *40:01 allele was seen between those with carbamazepine-induced MPE or DRESS and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.,HLA-B *40:01:01 is not associated with risk of Drug Hypersensitivity when treated with carbamazepine.,*40:01:01
180,HLA_B_1502,carbamazepine (PA448785),"DRESS. No significant differences in *15:02 allele frequency were seen between patients with carbamazepine-induced DRESS, and carbamazepine-tolerant patients or healthy population controls, either in a European or Chinese population.",HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.,*15:02:01
181,HLA_B_1502,lamotrigine (PA450164),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=8) and toxic epidermal necrolysis (TEN, n=1). No significant difference in the frequency of subjects with HLA-B*15:02 was seen between patients with lamotrigine-induced SJS/TEN and lamotrigine-tolerant controls. 3/9 patients with lamotrigine-induced SJS/TEN carried *15:02, compared to 11/123 lamotrigine-tolerant patients. Cases and controls from this study were pooled with patients from two other studies for the statistical analysis [PMID: 17509004, 20235791].",HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine in people with Epilepsy.,*15:02:01
182,HLA_B_1502,lamotrigine (PA450164),"No significant difference in the frequency of subjects with HLA-B*15:02 was seen between patients with lamotrigine-induced mild maculopapular eruption (MPE) and lamotrigine-tolerant controls or normal controls. The *15:02 allele frequency was 4.5% in those with lamotrigine-induced MPE, compared to 7.1% in lamotrigine-tolerant patients and 7.3% in normal controls.",HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with lamotrigine in people with Epilepsy.,*15:02:01
183,HLA_B_5901,acetazolamide (PA448018),"Case report. A woman developed Stevens-Johnson Syndrome (SJS) after treatment with acetazolamide following LASIK. HLA typing showed HLA-A24, HLA-A26, HLA-B59, HLA-B62 and HLA-Cw3. HLA-B59 has been detected in cases of methazolamide-induced SJS, and methazolamide is analagous to acetazolamide. This suggests that *59 may contribute to susceptibility to acetazolamide-induced SJS. *59:01 is used for this annotation since it is the first *59 allele discovered.",HLA-B *59:01:01:01 is associated with risk of Stevens-Johnson Syndrome when treated with acetazolamide.,*59:01:01:01
184,HLA_B_1502,carbamazepine (PA448785),Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=8) and toxic epidermal necrolysis (TEN; n=1). The frequency of the *15:02 allele was 100% (9/9) in patients with carbamazepine-induced SJS/TEN as compared to 13.75% in carbamazepine-tolerant controls (11/80) and 17.74% in healthy individuals (11/62).,HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
185,HLA_B_1502,carbamazepine (PA448785),"No significant difference in the frequency of the *15:02 allele was seen between patients with carbamazepine-induced maculopapular eruption (MPE) and carbamazepine-tolerant controls. 25.64% (10/39) of patients with MPE had the allele, as compared to 13.75% (11/80) of carbamazepine-tolerant individuals.",HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.,*15:02:01
186,HLA_A_3101,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 42% (5/9) of subjects with carbamazepine-induced SJS/TEN carried the *31:01 allele, as compared to 4% (10/257) of carbamazepine-tolerant controls.",HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
187,HLA_A_3101,carbamazepine (PA448785),"Hypersensitivity syndrome defined as the presence of a rash or liver involvement within 3 months after initiation of carbamazepine treatment, along with a minimum of two of the following manifestations: prolonged recovery phase despite drug withdrawal, fever, involvement of other internal organs, or presence of hematologic abnormalities. Patients who experienced carbamazepine-induced hypersensitivity syndrome had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.,*31:01:02
188,HLA_A_3101,carbamazepine (PA448785),"Patients with carbamazepine-induced maculopapular exanthema had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.",HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*31:01:02
189,HLA_B_1502,oxcarbazepine (PA450732),"4/9 (44.4%) of patients with oxcarbazepine-induced maculopapular eruption (MPE) carried the *15:02 allele, as compared to 6/72 (8.3%) of normal controls. No statistically significant difference in *15:02 frequency was seen between MPE patients and oxcarbazepine-tolerant controls (1/9 (11.1%) carried the allele).",HLA-B *15:02:01 is associated with increased risk of Maculopapular Exanthema when treated with oxcarbazepine in people with Epilepsy.,*15:02:01
190,HLA_A_3101,carbamazepine (PA448785),"Severe cutaneous adverse reactions (cADRs) included Stevens-Johnson Syndrome and toxic epidermal necrolysis (SJS/TEN; n=5), drug-induced hypersensitivity syndrome (DIHS; n=21), and various others (e.g. erythema multiforme; n=19) The *31:01 allele was present in 37/61 (60.7%) of patients with carbamazepine-induced cADRs, but only 47/376 (12.5%) of carbamazepine-tolerant controls. p-value for significance was set at 0.00263 (0.05/19). This association was replicated in a smaller cohort of 16 cases and 44 controls (p-value for significance set at 0.025 (0.05/2).",HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
191,HLA_A_7401,carbamazepine (PA448785),"HLA-A*74 was analyzed; specific alleles were not provided. *74:01 was used for this annotation since it was the first *74 allele discovered. Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *74 allele was present in 3/16 (18.8%) of patients with carbamazepine-induced SJS/TEN, but only 5/300 (1.7%) of normal controls. Bonferroni-corrected p-value.",HLA-A *74:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*74:01
192,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *15:02 allele was present in 12/16 (75%) of patients with carbamazepine-induced SJS/TEN, but only 47/300 (15.7%) of normal controls. Bonferroni-corrected p-value.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
193,HLA_B_1511,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=11) and toxic epidermal necrolysis (TEN; 3). 4/14 (28.5%) of patients with SJS/TEN (including probable SJS patients) carried the *15:11 allele, compared to an allele frequency of 0.01 in the Japanese population.",HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:11:01
194,HLA_B_1502,carbamazepine (PA448785),6 out of the 8 cases of carbamazepine-induced Stevens-Johnson Syndrome carried the *15:02 allele. None of the 10 normal controls carried the allele. The paper did not specify whether these were healthy population controls or carbamazepine-tolerant controls.,HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.,*15:02:01
195,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS; n=35) and toxic epidermal necrolysis (TEN; n=7). 37 of the 42 patients with SJS or TEN carried the *15:02 allele, compared to 5 of the 42 carbamazepine-tolerant controls.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
196,HLA_A_3101,carbamazepine (PA448785),"Hypersensitivity syndrome, with diagnostic criteria being skin rash, plus two of fever, lymphadenopathy, and hematologic abnormalities, with the involvement of at lest one internal organ. 59% of those with carbamazepine-induced hypersensitivity syndrome carried the *31:01 allele, as compared to 14% of carbamazepine-tolerant controls, and 10% of healthy population controls.",HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.,*31:01:02
197,HLA_A_3101,carbamazepine (PA448785),"Severe cutaneous adverse reactions (SCARs) included hypersensitivity syndrome (n=17) and Stevens-Johnson Syndrome (SJS; n=7). 54% of those with carbamazepine-induced SCARs carried the *31:01 allele, as compared to 14% of carbamazepine-tolerant controls, and 10% of healthy population controls.",HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*31:01:02
198,HLA_A_3101,carbamazepine (PA448785),"42.9% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 10.3% of the healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 14%).",HLA-A *31:01:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.,*31:01:02
199,HLA_A_0201,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (28%).",HLA-A *02:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*02:01:01:01
200,HLA_A_2402,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (28.6%), HSS (17.6%) or SCARs (20.8%) and carbamazepine-tolerant controls (42%).",HLA-A *24:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*24:02:01:01
201,HLA_A_3303,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (14.2%), HSS (29.4%) or SCARs (25%) and carbamazepine-tolerant controls (24%).",HLA-A *33:03:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*33:03:01
202,HLA_B_1502,carbamazepine (PA448785),"14.3% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 0.4% of the healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 0%).",HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.,*15:02:01
203,HLA_B_1511,carbamazepine (PA448785),"42.9% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 3.9% of healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 4%).",HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.,*15:11:01
204,HLA_B_1501,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (14.3%), HSS (23.5%) or SCARs (20.8%) and carbamazepine-tolerant controls (14%).",HLA-B *15:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:01:01:01
205,HLA_B_5101,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (23.5%) or SCARs (29.1%) and carbamazepine-tolerant controls (20%).",HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*51:01:01
206,HLA_B_5801,allopurinol (PA448320),"In patients with allopurinol sensitivity, the authors did not observe severe cutaneous adverse reactions, but did observe maculopapular eruptions (MPE). Of all the hematologic malignancies, those patients with chronic myelogenous leukemia had the highest risk of MPE.",HLA-B *58:01 is not associated with risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.,*58:01
207,HLA_B_4801,allopurinol (PA448320),"Note: the authors do not specify which HLA-B*48 allele was genotyped so it may not actually be HLA-B*48:01:01. In patients with allopurinol sensitivity, the authors did not observe severe cutaneous adverse reactions, but did observe maculopapular eruptions (MPE). Of all the hematologic malignancies, those patients with chronic myelogenous leukemia had the highest risk of MPE.",HLA-B *48:01:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.,*48:01:01
208,HLA_C_0801,allopurinol (PA448320),"Note: the authors do not specify which HLA-C* allele was genotyped so it may not actually be HLA-C*8:01:01(they state B48-Cw8). In patients with allopurinol sensitivity, the authors did not observe severe cutaneous adverse reactions, but did observe maculopapular eruptions (MPE). Of all the hematologic malignancies, those patients with chronic myelogenous leukemia had the highest risk of MPE.",HLA-C *08:01:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.,*08:01:01
209,HLA_DRB1_0901,allopurinol (PA448320),"Note: the authors only state that patients in the hypersensitive group had a higher frequency of being DR9 positive,so it may not actually be HLA-DRB1*09:01:02. In patients with allopurinol sensitivity, the authors did not observe severe cutaneous adverse reactions, but did observe maculopapular eruptions (MPE). Of all the hematologic malignancies, those patients with chronic myelogenous leukemia had the highest risk of MPE.",HLA-DRB1 *09:01:02 is associated with increased risk of Drug Hypersensitivity when exposed to allopurinol in people with Hematologic Neoplasms.,*09:01:02
210,HLA_C_0102,carbamazepine (PA448785),"Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (26%).",HLA-C *01:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.,*01:02:01
211,HLA_A_0201,carbamazepine (PA448785),"Patients with carbamazepine-induced maculopapular eruption had a higher frequency of the *02:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-A *02:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*02:01:01:01
212,HLA_A_3001,lamotrigine (PA450164),"Patients with lamotrigine-induced maculopapular eruption had a higher frequency of the *30:01 allele, as compared to those who were lamotrigine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-A *30:01:01 is associated with increased risk of Maculopapular Exanthema when treated with lamotrigine.,*30:01:01
213,HLA_A_3303,lamotrigine (PA450164),"Patients with lamotrigine-induced maculopapular eruption had a lower frequency of the *33:03 allele, as compared to those who were lamotrigine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-A *33:03:01 is associated with decreased risk of Maculopapular Exanthema when treated with lamotrigine.,*33:03:01
214,HLA_B_5801,carbamazepine (PA448785),"Patients with carbamazepine-induced maculopapular eruption had a lower frequency of the *58:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-B *58:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.,*58:01
215,HLA_B_1302,lamotrigine (PA450164),"Patients with lamotrigine-induced maculopapular eruption had a higher frequency of the *13:02 allele, as compared to those who were lamotrigine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-B *13:02:01 is associated with increased risk of Maculopapular Exanthema when treated with lamotrigine.,*13:02:01
216,HLA_DRB1_1405,carbamazepine (PA448785),"Patients with carbamazepine-induced maculopapular eruption had a higher frequency of the *14:05 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-DRB1 *14:05:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*14:05:01
217,HLA_DRB1_0301,carbamazepine (PA448785),"Patients with carbamazepine-induced maculopapular eruption had a lower frequency of the *03:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.",HLA-DRB1 *03:01:01:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.,*03:01:01:01
218,HLA_A_3303,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *33:03 allele, as compared to carbamazepine-tolerant controls.",HLA-A *33:03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*33:03:01
219,HLA_DRB1_1401,allopurinol (PA448320),"Note: the authors only state that patients in the hypersensitive group had a higher frequency of being DR14 positive,so it may not actually be HLA-DRB1*14:01:01. In patients with allopurinol sensitivity, the authors did not observe severe cutaneous adverse reactions, but did observe maculopapular eruptions (MPE). Of all the hematologic malignancies, those patients with chronic myelogenous leukemia had the highest risk of MPE.",HLA-DRB1 *14:01:01 is associated with increased risk of Drug Hypersensitivity when treated with allopurinol in people with Hematologic Neoplasms.,*14:01:01
220,HLA_B_1502,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*15:02:01
221,HLA_B_5801,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *58:01 allele, as compared to carbamazepine-tolerant controls.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*58:01
222,HLA_C_0302,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *03:02 allele, as compared to carbamazepine-tolerant controls.",HLA-C *03:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*03:02:01
223,HLA_DQB1_0303,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *03:03 allele, as compared to carbamazepine-tolerant controls.",HLA-DQB1 *03:03:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*03:03:02:01
224,HLA_DRB1_0701,carbamazepine (PA448785),"Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *07:01 allele, as compared to carbamazepine-tolerant controls.",HLA-DRB1 *07:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.,*07:01:01:01
225,HLA_A_3303,allopurinol (PA448320),"Association reported for the HLA-A*3303 allele. Sensitivity = 88.0%, Specificity = 73.7%, positive predictive value = 0.80% and negative predictive value = 99.96% (the latter two values were calculated on the assumption that prevalence of allopurinol-induced SCARs is 0.24%). N=22/26 patients with SCARs carried HLA-B*5801-C*0302-A*3303.",HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*33:03
226,HLA_A_0201,allopurinol (PA448320),A protective association was reported for the HLA-A*0201 allele.,HLA-A *02:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with allopurinol.,*02:01
227,HLA_B_1301,"carbamazepine (PA448785),""phenobarbital (PA450911)"",""phenytoin (PA450947)""",The frequency of the *1301 allele (25%) was higher compared to the frequency reported for the general population (1.3%) but was not statistically significant after correction for multiple comparisons.,"HLA-B *13:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine, phenobarbital or phenytoin in people with severe cutaneous adverse reactions.",*13:01:01
228,HLA_B_4801,"allopurinol (PA448320),""carbamazepine (PA448785)""",The frequency of the *4801 allele amoungst patients with DIHS/DRESS was higher compared to the frequency reported for the general population (4.3%) but was not statistically significant after correction for multiple comparisons.,HLA-B *48:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol or carbamazepine in people with severe cutaneous adverse reactions.,*48:01:01
229,HLA_C_0302,allopurinol (PA448320),"Association reported for the HLA-Cw*0302 allele. Sensitivity = 92.0%, Specificity = 87.7%, positive predictive value = 1.77% and negative predictive value = 99.98% (the latter two values were calculated on the assumption that prevalence of allopurinol-induced SCARs is 0.24%). N=22/26 patients with SCARs carried HLA-B*5801-C*0302-A*3303 and n=24/26 carried HLA-B*5801-C*0302.",HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:02
230,HLA_B_5801,allopurinol (PA448320),"The study also reported a significant association between delayed clearance of oxypurinol (allopurinol metabolite) and low estimated glomerular filtration rate (<30mL/min/1.73m^2, associated with kidney failure to severe renal impairment), which correlated with higher granulysin levels and poor prognosis in patients with SJS/TEN. Unclear whether other alleles were genotyped for.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
231,HLA_A_3303,allopurinol (PA448320),"Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*33:03
232,HLA_C_0302,allopurinol (PA448320),"Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:02
233,HLA_DPB1_0301,,"The frequency of HLA-DPB1*03:01 was 13.8% in patients with aspirin-induced asthma, as compared to 4.1% in patients with aspirin-tolerant asthma, and 2.2% in normal controls. These results remained significant after correction for multiple comparisons.",HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.,*03:01:01
234,HLA_DQB1_0501,,"No significant differences in frequencies of the HLA-DQB1*05:01 allele were seen between aspirin-induced asthmatics (3.3%) and aspirin-tolerant asthmatics (6.8%) or normal controls (8.8%) after correction for multiple testing. However, note that the difference between aspirin-induced asthmatics and normal controls was significant before correction (p=0.039; OR=0.4).",HLA-DQB1 *05:01:01:01 is not associated with risk of aspirin-induced asthma.,*05:01:01:01
235,HLA_DRB1_0301,,"No significant differences in frequencies of the HLA-DRB1*03:01 allele were seen between aspirin-induced asthmatics (5.9%) and aspirin-tolerant asthmatics (1.4%) or normal controls (2.2%) after correction for multiple testing. However, note that the difference between aspirin-induced asthmatics and aspirin-tolerant asthmatics was significant before correction (p=0.037; OR=9.7).",HLA-DRB1 *03:01:01:01 is not associated with risk of aspirin-induced asthma.,*03:01:01:01
236,HLA_DRB1_0901,,"No significant differences in frequencies of the HLA-DRB1*09:01 allele were seen between aspirin-induced asthmatics (18.4%) and aspirin-tolerant asthmatics (9.6%) or normal controls (9.4%) after correction for multiple testing. However, note that the differences were significant before correction (p=0.028 OR=2.3 and p=0.037 OR=2.2, respectively).",HLA-DRB1 *09:01:02 is not associated with risk of aspirin-induced asthma.,*09:01:02
237,HLA_DRB1_0301,allopurinol (PA448320),"Note: Alleles HLA-A*3303, HLA-C*0302, HLA-DRB1*0301 were in LD and formed an extended haplotype with HLA-B*5801. Chronic renal insufficiency was seen at a significantly higher frequency in patients with allopurinol-induced SCAR compared to allopurinol-tolerant patients p<0.0001 (OR=4.7 (2.3-9.3)).",HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:01
238,HLA_DPB1_0301,,"The frequency of the *03:01 allele was 19.5% in those with aspirin-induced asthma, as compared to 5.2% in normal controls and 4.4% in asthmatic controls. This difference withstood correction for multiple testing, but only when comparing aspirin-induced asthmatics with normal controls.",HLA-DPB1 *03:01:01 is associated with increased risk of aspirin-induced asthma.,*03:01:01
239,HLA_DPB1_0401,,"The frequency of the *04:01 allele was 28.8% in those with aspirin-induced asthma, as compared to 49.0% in normal controls and 45.6% in asthmatic controls. This difference withstood correction for multiple testing, but only when comparing aspirin-induced asthmatics with normal controls.",HLA-DPB1 *04:01:01:01 is associated with decreased risk of aspirin-induced asthma.,*04:01:01:01
240,HLA_DRB1_1101,,"The frequency of HLA-DRB1*11 allele was 10.9% in those with aspirin-induced asthma, as compared to 21.3% in normal controls and 20.8% in asthmatic controls. These were significant differences prior to correction for multiple testing (p=0.04 and 0.05, respectively), but were not significant after correction.",HLA-DRB1 *11:01:01 is not associated with risk of aspirin-induced asthma.,*11:01:01
241,HLA_DRB1_0301,,No significant difference in the frequency of the HLA-DRB1*03 allele was seen between aspirin-induced asthma subjects (12.7%) and normal healthy controls (5.3%).,HLA-DRB1 *03:01:01:01 is not associated with risk of aspirin-induced asthma.,*03:01:01:01
242,HLA_B_5801,allopurinol (PA448320),"Retrospective study looking at HLA-B allele frequencies in patients with SJS, TEN or SJS/TEN. The HLA-B*58:01 allele seemed to be enriched in patients treated with allopurinol (71.4% of patients had the allele compared to 28.6% without the allele), compared to compared to n=11 patients not treated with allopurinol (9.1% had the allele compared to 90.9% without the allele). No significant difference in disease manifestations between allopurinol users and nonusers was reported.","HLA-B *58:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.",*58:01
243,HLA_B_4403,lamotrigine (PA450164),"Retrospective study looking at HLA-B allele frequencies in patients with SJS, TEN or SJS/TEN. The HLA-B*44:03 allele seemed to be enriched in patients treated with lamotrigine (60% of patients had the allele compared to 40% without the allele), compared to n=13 patients not treated with lamotrigine (15.4% had the allele compared to 84.6% without the allele). No significant differences between lamotrigine users and nonusers was reported.","HLA-B *44:03:01 is associated with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine in people with Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome.",*44:03:01
244,HLA_C_0701,clozapine (PA449061),"The HLA-Cw7 serotype was more frequent in patients with clozapine-induced agranulocytosis as compared to clozapine-tolerant controls. Note that the annotation was completed on HLA-C*07:01:01 because the Cw7 serotype recognizes HLA-C*07 alleles, and *07:01:01 was the first *07 allele discovered.",HLA-C *07:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*07:01:01
245,HLA_DPB1_0401,clozapine (PA449061),The HLA-DPB*04:01 allele was more frequent in patients with clozapine-induced agranulocytosis as compared to clozapine-tolerant controls.,HLA-DPB1 *04:01:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*04:01:01:01
246,HLA_DQB1_0502,clozapine (PA449061),The HLA-DQB1*05:02 allele was more frequent in patients with clozapine-induced agranulocytosis as compared to clozapine-tolerant controls.,HLA-DQB1 *05:02:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*05:02:01
247,HLA_D_B302,clozapine (PA449061),The HLA-DRB3*02:02 allele was more frequent in patients with clozapine-induced agranulocytosis as compared to clozapine-tolerant controls.,HLA-DRB3 *02:02:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*02:02:01:01
248,HLA_DRB1_1501,"amoxicillin (PA448406),""clavulanate (PA164742987)""","There was a higher frequency of the HLA-DRB1*1501 allele in patients who experienced co-amoxiclav-associated jaundice, as compared to controls. The association was stronger when only considering patients homozygous for the HLA-DRB1*1501 allele. The authors note that all patients with the *1501 allele had the haplotype DRB1*1501-DRB5*0101-DQA1*0102-DQB1*0602. Please note that the allele frequencies listed below refer to prevalences, not actual frequencies, i.e. whether the patient has the *1501 allele, and whether the patient is homozygous for the *1501 allele.",HLA-DRB1 *15:01:01:01 is associated with increased risk of Jaundice when treated with amoxicillin and clavulanate.,*15:01:01:01
249,HLA_DPB1_0301,aspirin (PA448497),The frequency of the *03:01 allele was significantly higher in aspirin-intolerant asthma patients as compared to healthy controls or aspirin-intolerant urticaria patients.,HLA-DPB1 *03:01:01 is associated with increased risk of Asthma when treated with aspirin.,*03:01:01
250,HLA_DQB1_0609,aspirin (PA448497),"The frequency of the HLA-DRB1*1302-DQB1*0609 haplotype was significantly higher in aspirin-intolerant urticaria patients as compared to healthy controls. Frequencies listed are haplotype frequencies. Individuals with this haplotype also had a significantly higher atopy rate, higher mean serum total IgE level and younger age (p<0.05; data not shown) as compared to those without the haplotype.",HLA-DQB1 *06:09 is associated with increased risk of Urticaria when treated with aspirin.,*06:09
251,HLA_DRB1_1302,aspirin (PA448497),"The frequency of the HLA-DRB1*1302-DQB1*0609 haplotype was significantly higher in aspirin-intolerant urticaria patients as compared to healthy controls. Frequencies listed are haplotype frequencies. Individuals with this haplotype also had a significantly higher atopy rate, higher mean serum total IgE level and younger age (p<0.05; data not shown) as compared to those without the haplotype.",HLA-DRB1 *13:02:01 is associated with increased risk of Urticaria when treated with aspirin.,*13:02:01
252,HLA_DPB1_0301,aspirin (PA448497),"The frequency of the *03:01 allele was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma. However, this was no longer significant after correction for multiple comparisons.",HLA-DPB1 *03:01:01 is associated with decreased risk of Urticaria when treated with aspirin.,*03:01:01
253,HLA_DRB1_0101,clozapine (PA449061),The HLA-DRB1*01:01 allele was less frequent in patients with clozapine-induced agranulocytosis as compared to clozapine-tolerant controls.,HLA-DRB1 *01:01:01 is associated with decreased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*01:01:01
254,HLA_DRB1_0901,aspirin (PA448497),"The frequency of the *09:01 allele was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma, though this was no longer significant after correction for multiple comparisons. However, the frequency of the haplotype DRB1*0901-DQB1*0303-DPB1*0501 was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma.",HLA-DRB1 *09:01:02 is associated with decreased risk of Urticaria when treated with aspirin.,*09:01:02
255,HLA_DPB1_0501,aspirin (PA448497),"The frequency of the *05:01 allele was significantly lower in patients with aspirin-induced urticaria as compared to normal healthy controls, though this was no longer significant after correction for multiple comparisons. However, the frequency of the haplotype DRB1*0901-DQB1*0303-DPB1*0501 was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma.",HLA-DPB1 *05:01:01 is associated with decreased risk of Urticaria when treated with aspirin.,*05:01:01
256,HLA_DPB1_1301,aspirin (PA448497),"The frequency of the *13:01 allele was significantly lower in patients with aspirin-induced urticaria as compared to normal healthy controls. However, this was no longer significant after correction for multiple comparisons.",HLA-DPB1 *13:01 is associated with decreased risk of Urticaria when treated with aspirin.,*13:01
257,HLA_DRB1_0101,nevirapine (PA450616),The frequency of the HLA-DRB1*01 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a White population. No significant results were seen for Asians or Blacks. Note that this annotation was done on HLA-DRB1*01:01:01 because this was the first *01 allele discovered. p-value corrected for multiple testing.,HLA-DRB1 *01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.,*01:01:01
258,HLA_C_0401,nevirapine (PA450616),The HLA-Cw*04 allele group was more frequent in those who experienced a nevirapine hypersensitivity reaction as compared to nevirapine tolerant patients. Significant in univariate and multivariate logistic regression (p-value and OR below for multivariate logistic regression). Note that this annotation was created on HLA-C*04:01:01:01 because this was the first *04 allele discovered.,HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*04:01:01:01
259,HLA_DRB1_1501,nevirapine (PA450616),"The HLA-DRB1*15 allele group was less frequent in those who experienced a nevirapine hypersensitivity reaction as compared to nevirapine tolerant patients. This allele was significant in univariate logistic regression (p-value and OR listed below), but was no longer significant in multivariate logistic regression when HLA-Cw*04 was included (data not shown in paper). Note that this annotation was created on HLA-DRB1*15:01:01:01 because this was the first *15 allele discovered.",HLA-DRB1 *15:01:01:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*15:01:01:01
260,HLA_DQB1_0609,aspirin (PA448497),"The frequency of the *06:09 allele was significantly higher in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma or normal healthy controls. Please note that this allele was also significantly associated with younger age (p=0.001) and that patients with the allele tended toward having increased total IgE levels (p=0.06). Additionally, the frequency of the haplotype DRB1*1302-DQB1*0609-DPB1*0201 was also significantly higher in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma or normal healthy controls.",HLA-DQB1 *06:09 is associated with increased risk of Urticaria when treated with aspirin.,*06:09
261,HLA_DQB1_0604,aspirin (PA448497),"The frequency of the *06:04 allele was significantly higher in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma. However, this was no longer significant after correction for multiple comparisons.",HLA-DQB1 *06:04:01 is associated with increased risk of Urticaria when treated with aspirin.,*06:04:01
262,HLA_A_0201,egfr inhibitors (PA153561371),"In multivariate logistic regression, HLA-A*02:01 was associated with a lower risk for development of skin rash. Patients with skin rash had a lower frequency of the allele as compared to those without skin rash. Significant after Bonferroni correction (significance level = 0.0125).",HLA-A *02:01 is associated with decreased risk of Exanthema when treated with egfr inhibitors in people with Neoplasms.,*02:01
263,HLA_DRB1_1302,aspirin (PA448497),"The frequency of the *13:02 allele was significantly higher in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma or normal healthy controls. Please note that this allele was also significantly associated with younger age (p<0.0001) and that patients with the allele tended toward having increased total IgE levels (p=0.10). Additionally, the frequency of the haplotype DRB1*1302-DQB1*0609-DPB1*0201 was also significantly higher in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma or normal healthy controls.",HLA-DRB1 *13:02:01 is associated with increased risk of Urticaria when treated with aspirin.,*13:02:01
264,HLA_C_0801,nevirapine (PA450616),The HLA-Cw8 antigen was more frequent in patients who were nevirapine hypersensitive as compared to those who were nevirapine tolerant. Note that this annotation was done on HLA-C*08:01 because the HLA-Cw8 antigen recognizes *08 alleles and *08:01 was the first *08 allele discovered.,HLA-C *08:01 is associated with increased risk of Hypersensitivity when treated with nevirapine in people with HIV.,*08:01
265,HLA_DQB1_0303,aspirin (PA448497),"The frequency of the *03:03 allele was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma, though this was no longer significant after correction for multiple comparisons. However, the frequency of the haplotype DRB1*0901-DQB1*0303-DPB1*0501 was significantly lower in patients with aspirin-induced urticaria as compared to those with aspirin-intolerant asthma.",HLA-DQB1 *03:03:02:01 is associated with decreased risk of Urticaria when treated with aspirin.,*03:03:02:01
266,HLA_A_0301,egfr inhibitors (PA153561371),"In multivariate logistic regression, HLA-A*03:01 was associated with a lower risk for development of skin rash. Patients with skin rash had a lower frequency of the allele as compared to those without skin rash. Significant after Bonferroni correction (significance level = 0.0125).",HLA-A *03:01:01:01 is associated with decreased risk of Exanthema when treated with egfr inhibitors in people with Neoplasms.,*03:01:01:01
267,HLA_A_0201,egfr inhibitors (PA153561371),The HLA-A*02:01 allele was not associated with overall survival rates in patients taking EGFR inhibitors.,HLA-A *02:01 is not associated with overall survival when treated with egfr inhibitors in people with Neoplasms.,*02:01
268,HLA_A_0301,egfr inhibitors (PA153561371),The HLA-A*03:01 allele was not associated with overall survival rates in patients taking EGFR inhibitors.,HLA-A *03:01:01:01 is not associated with overall survival when treated with egfr inhibitors in people with Neoplasms.,*03:01:01:01
269,HLA_C_0401,Drugs For Treatment Of Tuberculosis (PA164712708),"The frequency of the HLA-Cw*04:01 allele was higher in cases of antituberculosis drug (ATD)-induced hypersensitivity syndrome (HSS) as compared to ATD-tolerant controls and the general population. Results were also significant when combining *04:01 with HLA-A*11:01, and *04:01 with HLA-A*11:01 and HLA-B*15:01. p-values corrected for multiple testing.",HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.,*04:01:01:01
270,HLA_C_0401,nevirapine (PA450616),"The frequency of the *04:01 allele was greater in those who developed Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) on nevirapine, as compared to nevirapine-tolerant controls. Results were also significant when considering the HLA-C*04:01-HLA-B*53:01:01 haplotype.","HLA-C *04:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.",*04:01:01:01
271,HLA_C_0401,nevirapine (PA450616),"The *04:01 allele was associated with an increased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-C *04:01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*04:01:01:01
272,HLA_DQB1_0501,nevirapine (PA450616),The frequency of the *05:01:01 allele was lower in those with nevirapine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to nevirapine-tolerant patients.,"HLA-DQB1 *05:01:01:01 is associated with decreased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with nevirapine in people with HIV.",*05:01:01:01
273,HLA_DQB1_0201,nevirapine (PA450616),"The *02:01G allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group. (The ""G"" represents ambiguous allele typings, see http://hla.alleles.org/alleles/g_groups.html).",HLA-DQB1 *02:01:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*02:01:01
274,HLA_DQB1_0201,nevirapine (PA450616),"The *02:01 allele was associated with a decreased risk for developing nevirapine-induced drug-induced liver injury (DILI), when compared against the baseline ""rare allele"" group. (The ""G"" represents ambiguous allele typings, see http://hla.alleles.org/alleles/g_groups.html).",HLA-DQB1 *02:01:01 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV.,*02:01:01
275,HLA_DQB1_0302,nevirapine (PA450616),"The *03:02:01 allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *03:02:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*03:02:01
276,HLA_DQB1_0501,nevirapine (PA450616),"The *05:01:01 allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *05:01:01:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*05:01:01:01
277,HLA_DQB1_0302,nevirapine (PA450616),"The *03:02:01 allele was associated with a decreased risk for developing drug reaction with eosinophilia and systemic symptoms (DRESS, also known as hypersensitivity syndrome (HSS)), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *03:02:01 is associated with decreased risk of drug reaction with eosinophilia and systemic symptoms when treated with nevirapine in people with HIV.,*03:02:01
278,HLA_DQB1_0602,nevirapine (PA450616),"The *06:02 allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *06:02:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*06:02:01
279,HLA_DRB1_0101,"efavirenz (PA449441),""nevirapine (PA450616)""",The frequency of HLA-DRB1*01 was higher in patients with nevirapine/efavirenz hypersensitivity (isolated skin rash) as compared to nevirapine/efavirenz-tolerant patients. Note that this annotation was done on HLA-DRB*01:01:01 because this was the first *01 allele discovered. p-value corrected for multiple comparisons using Bonferroni.,HLA-DRB1 *01:01:01 is associated with increased risk of Exanthema when treated with efavirenz or nevirapine in people with HIV.,*01:01:01
280,HLA_C_0401,nevirapine (PA450616),"The frequency of HLA-Cw*04 alleles was significantly higher in those with nevirapine-induced rashes as compared to nevirapine-tolerant patients. However, this association was no longer significant after Bonferroni correction (p=0.088). Note that this annotation was done on HLA-C*04:01:01:01 because this was the first *04 allele discovered.",HLA-C *04:01:01:01 is associated with increased risk of Exanthema when treated with nevirapine in people with HIV.,*04:01:01:01
281,HLA_C_0302,nevirapine (PA450616),"The frequency of HLA-Cw*03 alleles was significantly lower in those with nevirapine-induced rashes as compared to nevirapine-tolerant patients. However, this association was no longer significant after Bonferroni correction (p=0.15). Note that this annotation was done on HLA-C*03:02 because this was the first *03 allele discovered.",HLA-C *03:02 is associated with decreased risk of Exanthema when treated with nevirapine in people with HIV.,*03:02
282,HLA_DQA1_0201,lapatinib (PA152241907),The HLA-DQA1*02:01 allele was present at a higher frequency in women with with ALT elevation (baseline ALT measurement within the upper limit of normal (ULN) range (<=1 x ULN) and one or more on-treatment ALT measurements > 3 x ULN) as compared to controls (ALT <= 1 times the upper limit of normal when exposed to lapatinib for at least 13 weeks). p-value after Bonferroni correction.,HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.,*02:01
283,HLA_DQA1_0201,letrozole (PA450196),No significant difference in the frequency of the HLA-DQA1*02:01 allele was seen between women with with ALT elevation (baseline ALT measurement within the upper limit of normal (ULN) range (<=1 x ULN) and one or more on-treatment ALT measurements > 3 x ULN) as compared to controls (ALT <= 1 times the upper limit of normal when exposed to letrozole for at least 13 weeks).,HLA-DQA1 *02:01 is not associated with risk of Toxic liver disease when treated with letrozole in women with Breast Neoplasms.,*02:01
284,HLA_DRB1_1101,"Antiinflammatory agents, non-steroids (PA164712462)","There was a higher frequency of the HLA-DR11 alleles In patients who experienced anaphylactoid reactions after NSAID administration as compared to NSAID tolerant patients (n=138) and NSAID tolerant patients who had IgE-mediated anaphylaxis to different agents (n=29). Note that this annotation was completed on HLA-DRB1*11:01:01 because the DR11 serotype recognizes HLA-DRB1*11 alleles, and *11:01:01 was the first *11 allele discovered.","HLA-DRB1 *11:01:01 is associated with increased risk of anaphylactoid reaction when treated with Antiinflammatory agents, non-steroids.",*11:01:01
285,HLA_B_3501,nevirapine (PA450616),"The frequency of the HLA-B*35 allele was greater in those with nevirapine-related hepatic adverse events as compared to healthy controls when considering a Thai population. No significant results were seen for Asians (non-Thai), Blacks or Whites (p corrected = 0.053, 1.0, 1.0, respectively). Note that this annotation was done on HLA-B*35:01:01:01 because this was the first *35 allele discovered. p-value corrected for multiple testing.",HLA-B *35:01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.,*35:01:01:01
286,HLA_C_0401,nevirapine (PA450616),The frequency of the HLA-Cw*04 allele was greater in those with nevirapine-related cutaneous adverse events as compared to healthy controls. Note that this annotation was done on HLA-C*04:01:01:01 because this was the first *04 allele discovered. p-value corrected for multiple testing.,HLA-C *04:01:01:01 is associated with increased risk of Drug Toxicity when treated with nevirapine in people with HIV.,*04:01:01:01
287,HLA_B_4601,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B46 by low resolution HLA DNA typing*.",HLA-B *46:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*46:01:01
288,HLA_B_4801,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B48 by low resolution HLA DNA typing*.",HLA-B *48:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*48:01
289,HLA_B_5101,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B51 by low resolution HLA DNA typing*.",HLA-B *51:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*51:01:01
290,HLA_B_5201,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B52 by low resolution HLA DNA typing*.",HLA-B *52:01:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*52:01:01:01
291,HLA_B_5401,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B54 by low resolution HLA DNA typing*.",HLA-B *54:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*54:01:01
292,HLA_B_5501,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B55 by low resolution HLA DNA typing*.",HLA-B *55:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*55:01:01
293,HLA_B_5601,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B56 by low resolution HLA DNA typing*.",HLA-B *56:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*56:01:01
294,HLA_A_3303,ticlopidine (PA451686),"The *33:03 allele was more frequent in those with ticlopidine-induced hepatotoxicity, as compared to ticlopidine-tolerant patients. Significant results were also seen when considering cholestatic hepatotoxicity, and when *33:03 was part of the haplotype HLA-A*3303-B*4403-Cw*1403-DRB1*1302-DQB1*0604. p-values corrected for multiple comparisons for individual *33:03 allele ONLY.",HLA-A *33:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.,*33:03
295,HLA_B_4403,ticlopidine (PA451686),"The *44:03 allele was more frequent in those with ticlopidine-induced hepatotoxicity, as compared to ticlopidine-tolerant patients. Significant results were also seen when considering cholestatic hepatotoxicity, and when *44:03 was part of the haplotype HLA-A*3303-B*4403-Cw*1403-DRB1*1302-DQB1*0604. p-values corrected for multiple comparisons for individual *44:03 allele ONLY.",HLA-B *44:03:01 is associated with increased risk of Toxic liver disease when treated with ticlopidine.,*44:03:01
296,HLA_C_1403,ticlopidine (PA451686),"The *14:03 allele was more frequent in those with ticlopidine-induced hepatotoxicity, as compared to ticlopidine-tolerant patients. Significant results were also seen when considering cholestatic hepatotoxicity, and when *14:03 was part of the haplotype HLA-A*3303-B*4403-Cw*1403-DRB1*1302-DQB1*0604. p-values corrected for multiple comparisons for individual *14:03 allele ONLY.",HLA-C *14:03 is associated with increased risk of Toxic liver disease when treated with ticlopidine.,*14:03
297,HLA_DQB1_0604,ticlopidine (PA451686),"The *06:04 allele was more frequent in those with ticlopidine-induced hepatotoxicity, as compared to ticlopidine-tolerant patients. Significant results were also seen when considering cholestatic hepatotoxicity, and when *06:04 was part of the haplotype HLA-A*3303-B*4403-Cw*1403-DRB1*1302-DQB1*0604. p-values corrected for multiple comparisons for individual *06:04 allele ONLY.",HLA-DQB1 *06:04:01 is associated with increased risk of Toxic liver disease when treated with ticlopidine.,*06:04:01
298,HLA_DRB1_1302,ticlopidine (PA451686),"The *13:02 allele was more frequent in those with ticlopidine-induced hepatotoxicity, as compared to ticlopidine-tolerant patients. Significant results were also seen when considering cholestatic hepatotoxicity, and when *13:02 was part of the haplotype HLA-A*3303-B*4403-Cw*1403-DRB1*1302-DQB1*0604. p-values corrected for multiple comparisons for individual *13:02 allele ONLY.",HLA-DRB1 *13:02:01 is associated with increased risk of Toxic liver disease when treated with ticlopidine.,*13:02:01
299,HLA_DQB1_0202,acetaminophen (PA448015),P-value was no longer significant after correction for multiple comparisons.,"HLA-DQB1 *02:02 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*02:02
300,HLA_DRB1_1502,acetaminophen (PA448015),,"HLA-DRB1 *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*15:02:01
301,HLA_DRB1_0405,acetaminophen (PA448015),Allele reported as *04:05.,"HLA-DRB1 *04:05:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*04:05:01
302,HLA_DRB1_1101,acetaminophen (PA448015),Allele described as *11:01.,"HLA-DRB1 *11:01:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*11:01:01
303,HLA_DRB1_1302,acetaminophen (PA448015),Allele described as *13:02.,"HLA-DRB1 *13:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*13:02:01
304,HLA_A_3303,allopurinol (PA448320),Please note: the association reported was with HLA-A33 (allele subtype was not defined- here we use *33:03 as other associations have been shown). *Unclear if p-values are corrected for multiple testing.*,"HLA-A *33:03 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.",*33:03
305,HLA_B_5801,allopurinol (PA448320),"Please note: the association reported was with HLA-B*58 (allele subtype was not defined). Authors stated ""Korea is one of the countries with a high frequency of HLA-B*5801 which is the only subtype of HLA-B58 in the Korean population."" Freq in healthy controls given as 12.2%. *Unclear if p-values are corrected for multiple testing.*","HLA-B *58:01 is not associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.",*58:01
306,HLA_B_1502,phenobarbital (PA450911),"Children who carried the *15:02 allele did not have an increased risk of developing phenobarbital-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).",HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenobarbital in children.,*15:02:01
307,HLA_B_1502,phenytoin (PA450947),"Children who carried the *15:02 allele did not have an increased risk of developing phenytoin-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).",HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin in children.,*15:02:01
308,HLA_B_1502,"carbamazepine (PA448785),""phenobarbital (PA450911)"",""phenytoin (PA450947)""","Carbamazepine n=3, phenobarbital n=20, phenytoin n=17. Children who carried the *15:02 allele did not have an increased risk of developing antiepileptic-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Negative results were also seen when considering phenobarbital and phenytoin subgroups.","HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.",*15:02:01
309,HLA_C_0801,acetaminophen (PA448015),,HLA-C *08:01 is not associated with increased likelihood of Stevens-Johnson Syndrome when treated with acetaminophen.,*08:01
310,HLA_C_0302,acetaminophen (PA448015),,"HLA-C *03:02 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*03:02
311,HLA_C_0302,allopurinol (PA448320),Please note: the association reported was with HLA-Cw3 (allele subtype was not defined- here we use *03:02). *Unclear if p-values are corrected for multiple testing.*,"HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.",*03:02
312,HLA_A_3101,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A31 by low resolution HLA DNA typing*.",HLA-A *31:01:02 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*31:01:02
313,HLA_B_5901,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B59 by low resolution HLA DNA typing*.",HLA-B *59:01:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*59:01:01:01
314,HLA_B_6701,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B67 by low resolution HLA DNA typing*.",HLA-B *67:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*67:01:01
315,HLA_B_4002,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4002.,HLA-B *40:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*40:02:01
316,HLA_B_4003,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4003.,HLA-B *40:03 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*40:03
317,HLA_B_4006,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4006.,HLA-B *40:06:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*40:06:01:01
318,HLA_B_4403,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4403.,HLA-B *44:03:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*44:03:01
319,HLA_B_4601,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4601.,HLA-B *46:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*46:01:01
320,HLA_B_5101,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 5101.,HLA-B *51:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*51:01:01
321,HLA_B_5201,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 5201.,HLA-B *52:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*52:01:01:01
322,HLA_B_5401,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 5401.,HLA-B *54:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*54:01:01
323,HLA_B_5801,allopurinol (PA448320),The allele was found at a significantly higher frequency in patients with allopurinol-induced severe cutaneous adverse reactions compared to healthy controls. No significant difference in allele frequency was found between n=133 allopurinol-tolerant patients and healthy controls (p=0.1547).,HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
324,HLA_B_1518,oxcarbazepine (PA450732),Case report. A 9-year-old child prescribed oxcarbazepine developed Stevens-Johnson Syndrome. Genotyping showed HLA-B*1518/HLA-B*4001.,HLA-B *15:18:01/*40:01:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in children with Seizures.,*15:18:01/*40:01:01
325,HLA_B_1518,oxcarbazepine (PA450732),Case report. A 38-year-old female given oxcarbazepine developed Stevens-Johnson Syndrome. Genotyping showed HLA-B*1518/HLA-B*4001.,HLA-B *15:18:01/*40:01:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in women with Seizures.,*15:18:01/*40:01:01
326,HLA_B_5602,phenytoin (PA450947),"Case report. A 32-year old man, 33-year-old man and 43-year-old woman, all Indigenous Australian, presented with drug-induced hypersensitivity syndrome (DIHS; also known as drug reaction with eosinophilia and systemic symptoms (DRESS)) after receiving phenytoin. Genotyping revealed that all three patients carried the HLA-B*56:02 allele, with one patient being homozygous for the allele.",HLA-B *56:02 is associated with drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.,*56:02
327,HLA_B_4801,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4801.,HLA-B *48:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*48:01
328,HLA_B_0702,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant.,HLA-B *07:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*07:02:01
329,HLA_B_1501,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele reported as 1501.,HLA-B *15:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*15:01:01:01
330,HLA_B_1518,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 1518.,HLA-B *15:18:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*15:18:01
331,HLA_B_1527,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 1527.,HLA-B *15:27:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*15:27:01
332,HLA_B_1502,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned).,"HLA-B *15:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*15:02:01
333,HLA_B_1301,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned).,"HLA-B *13:01:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*13:01:01
334,HLA_B_1802,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned).,"HLA-B *18:02 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*18:02
335,HLA_B_3802,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned).,"HLA-B *38:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*38:02:01
336,HLA_B_4001,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned). Allele described as 40:01.,"HLA-B *40:01:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*40:01:01
337,HLA_B_4601,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned). Allele described as 46:01.,"HLA-B *46:01:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*46:01:01
338,HLA_B_4101,allopurinol (PA448320),,"HLA-B *41:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*41:01
339,HLA_DQB1_0202,allopurinol (PA448320),,"HLA-DQB1 *02:02 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*02:02
340,HLA_DQB1_0502,allopurinol (PA448320),Statistics only given for the haplotype with HLA-DRB1*15:02. Allele reported as *05:02.,"HLA-DQB1 *05:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*05:02:01
341,HLA_DRB1_1502,allopurinol (PA448320),"For single allele analysis, the p-value was no longer significant after correction for multiple comparisons, however, the haplotype HLA-DRB1-*15:02-HLA-DQB1*05:02 was found at a significantly higher frequency in patients with SCAR compared to controls, and this remained significant after correction for multiple comparisons. Allele reported as *15:02.","HLA-DRB1 *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*15:02:01
342,HLA_DRB1_0405,allopurinol (PA448320),Allele reported as *04:05.,"HLA-DRB1 *04:05:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*04:05:01
343,HLA_B_5101,allopurinol (PA448320),A p-value of <0.05 was considered statistically significant (whether the p-value was corrected for multiple testing was not mentioned). Allele described as *51:01.,"HLA-B *51:01:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.",*51:01:01
344,HLA_A_0201,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A2 by low resolution HLA DNA typing*.",HLA-A *02:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*02:01
345,HLA_A_1101,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A11 by low resolution HLA DNA typing*.",HLA-A *11:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*11:01:01
346,HLA_A_2402,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A24 by low resolution HLA DNA typing*.",HLA-A *24:02:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*24:02:01:01
347,HLA_A_2601,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A26 by low resolution HLA DNA typing*.",HLA-A *26:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*26:01:01
348,HLA_A_3301,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-A33 by low resolution HLA DNA typing*.",HLA-A *33:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*33:01:01
349,HLA_B_0702,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B7 by low resolution HLA DNA typing*.",HLA-B *07:02:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*07:02:01
350,HLA_B_1301,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B13 by low resolution HLA DNA typing*.",HLA-B *13:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*13:01:01
351,HLA_B_3501,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B35 by low resolution HLA DNA typing*.",HLA-B *35:01:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*35:01:01:01
352,HLA_DRB1_1101,allopurinol (PA448320),Allele described as *11:01.,"HLA-DRB1 *11:01:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*11:01:01
353,HLA_DRB1_1302,allopurinol (PA448320),"P-value was no longer significant after correction for multiple comparisons, however analysis of HLA-B*58:01-DRB1*13:02 haplotype was significant after correction for the number of comparisons. Allele described as *13:02.","HLA-DRB1 *13:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol in people with Drug Hypersensitivity.",*13:02:01
354,HLA_A_3303,acetaminophen (PA448015),,"HLA-A *33:03 is not associated with increased likelihood of Stevens-Johnson Syndrome or Epidermal Necrolysis, Toxic when treated with acetaminophen.",*33:03
355,HLA_B_5801,acetaminophen (PA448015),,"HLA-B *58:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with acetaminophen.",*58:01
356,HLA_B_4101,acetaminophen (PA448015),,"HLA-B *41:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with acetaminophen.",*41:01
357,HLA_A_3303,allopurinol (PA448320),Please note: the association reported was with HLA-A33 (allele subtype was not defined- here we use *33:03 as other associations have been shown). *Unclear if p-values are corrected for multiple testing.*,"HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol in people with Kidney Failure, Chronic.",*33:03
358,HLA_B_1502,carbamazepine (PA448785),Meta-analysis with 15 studies. Cases were compared against drug-tolerant controls.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.",*15:02:01
359,HLA_A_3101,carbamazepine (PA448785),"Meta-analysis, number of studies included was not given.","HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.",*31:01:02
360,HLA_B_1502,carbamazepine (PA448785),Meta-analysis with 4 studies. Cases were compared against drug-tolerant controls.,HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.,*15:02:01
361,HLA_C_0302,allopurinol (PA448320),Please note: the association reported was with HLA-Cw3 (allele subtype was not defined- here we use *03:02). *Unclear if p-values are corrected for multiple testing.*,"HLA-C *03:02 is associated with increased risk of Exanthema when treated with allopurinol in people with Kidney Failure, Chronic.",*03:02
362,HLA_B_3701,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B37 by low resolution HLA DNA typing*.",HLA-B *37:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*37:01:01
363,HLA_A_2402,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 2402 - here we use 24:02:01:01.,HLA-A *24:02:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*24:02:01:01
364,HLA_A_3101,allopurinol (PA448320),Variant described as 3101. P-values <5.62E-8 were considered statistically significant.,HLA-A *31:01:02 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*31:01:02
365,HLA_A_0201,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant.,HLA-A *02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*02:01
366,HLA_A_0206,allopurinol (PA448320),Variant described as 0206. P-values <5.62E-8 were considered statistically significant.,HLA-A *02:06:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*02:06:01
367,HLA_A_0207,allopurinol (PA448320),Variant described as 0207. P-values <5.62E-8 were considered statistically significant.,HLA-A *02:07:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*02:07:01
368,HLA_A_0210,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant.,HLA-A *02:10 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*02:10
369,HLA_A_1101,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 11:01.,HLA-A *11:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*11:01:01
370,HLA_A_2601,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 2601 - here we use HLA-A*26:01:01 to represent this.,HLA-A *26:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*26:01:01
371,HLA_A_2602,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant.,HLA-A *26:02 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*26:02
372,HLA_B_3901,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B39 by low resolution HLA DNA typing*.",HLA-B *39:01:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*39:01:01:01
373,HLA_B_4402,allopurinol (PA448320),"7 patients with ADRs; two with Stevens-Johnson syndrome (SJS), one with SJS ocular type, four with erythema exudativum multiforme (EEM) minor. *Note: association for HLA-B44 by low resolution HLA DNA typing*.",HLA-B *44:02:01:01 is not associated with increased risk of erythema exudativum multiforme and Stevens-Johnson Syndrome when treated with allopurinol in people with Hyperuricemia.,*44:02:01:01
374,HLA_B_1502,"carbamazepine (PA448785),""phenobarbital (PA450911)"",""phenytoin (PA450947)"",""zonisamide (PA451978)""",This allele was not observed in any of the patients.,"HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.",*15:02:01
375,HLA_B_0702,"carbamazepine (PA448785),""phenobarbital (PA450911)"",""phenytoin (PA450947)"",""zonisamide (PA451978)""",This allele was not observed in any of the patients.,"HLA-B *07:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.",*07:02:01
376,HLA_B_5801,allopurinol (PA448320),The HLA-B*58:01 allele was found in one of three patients treated with allopurinol. Two patients had the *48:01 allele. The authors discuss that the strong association between allopurinol and HLA-B*50:01 was not found in this Japanese population of DIHS/DRESS patients.,HLA-B *58:01 is not associated with increased risk of Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol in people with severe cutaneous adverse reactions.,*58:01
377,HLA_B_5601,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 5601.,HLA-B *56:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*56:01:01
378,HLA_C_0102,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0102.,HLA-C *01:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*01:02:01
379,HLA_C_0303,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0303.,HLA-C *03:03:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:03:01
380,HLA_C_0304,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0304.,HLA-C *03:04:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*03:04:01:01
381,HLA_C_0401,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0401.,HLA-C *04:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*04:01:01:01
382,HLA_B_3801,clozapine (PA449061),"The presence of the HLA-B38 serotype was associated with an increased likelihood of experiencing clozapine-induced agranulocytosis, both in an exclusively Ashkenazi Jewish cohort (n=22) and in a Jewish and non-Jewish overall cohort (n=31). Note that this annotation was completed on HLA-B*38:01:01 because the B38 serotype recognizes HLA-B*38 alleles, and *38:01:01 was the first *38 allele discovered. Additionally, the haplotype HLA-B38, HLA-DR4 and HLA-DQ3 was also significantly associated with an increased risk for agranulocytosis, though HLA-DR4 and HLA-DQ3 were not individually associated (see annotations below). p-value for significance was set at 0.005.",HLA-B *38:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with schizoaffective disorder or Schizophrenia.,*38:01:01
383,HLA_DQB1_0301,clozapine (PA449061),"No significant association was seen between the presence of the HLA-DQ3 serotype and likelihood of experiencing clozapine-induced agranulocytosis, either in an exclusively Ashkenazi Jewish cohort (n=22) or in a Jewish and non-Jewish overall cohort (n=31). Note that this annotation was completed on HLA-DQB1*03:01:01:01 because the DQ3 serotype recognizes HLA-DQB1*03 alleles, and *03:01:01:01 was the first *03 allele discovered. However, the haplotype HLA-B38, HLA-DR4, HLA-DQ3 was also significantly associated with an increased risk for agranulocytosis (see annotation on HLA-B*38:01:01 above). p-value for significance was set at 0.005.",HLA-DQB1 *03:01:01:01 is not associated with risk of Agranulocytosis when treated with clozapine in people with schizoaffective disorder or Schizophrenia.,*03:01:01:01
384,HLA_DRB1_0401,clozapine (PA449061),"No significant association was seen between the presence of the HLA-DR4 serotype and likelihood of experiencing clozapine-induced agranulocytosis, either in an exclusively Ashkenazi Jewish cohort (n=22) or in a Jewish and non-Jewish overall cohort (n=31). Note that this annotation was completed on HLA-DRB1*04:01:01 because the DR4 serotype recognizes HLA-DRB1*04 alleles, and *04:01:01 was the first *04 allele discovered. However, the haplotype HLA-B38, HLA-DR4, HLA-DQ3 was also significantly associated with an increased risk for agranulocytosis (see annotation on HLA-B*38:01:01 above). p-value for significance was set at 0.005.",HLA-DRB1 *04:01:01 is not associated with risk of Agranulocytosis when treated with clozapine in people with schizoaffective disorder or Schizophrenia.,*04:01:01
385,HLA_A_6801,lamotrigine (PA450164),"Please note that this allele did not meet the adjusted significance threshold of 0.00016. The frequency of the HLA-A*68:01 allele was significantly higher in those with lamotrigine-induced severe cutaneous adverse reactions (SCARs), as compared to lamotrigine-tolerant controls or population controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction.",HLA-A *68:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*68:01:01:01
386,HLA_B_1502,oxcarbazepine (PA450732),Meta-analysis with three studies. Cases were compared against drug-tolerant controls.,HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with oxcarbazepine.,*15:02:01
387,HLA_B_1502,lamotrigine (PA450164),Meta-analysis with four studies. Cases were compared against drug-tolerant controls.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.",*15:02:01
388,HLA_B_1502,phenytoin (PA450947),Meta-analysis with four studies. Cases were compared against drug-tolerant controls.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:02:01
389,HLA_B_1502,lamotrigine (PA450164),Meta-analysis with two studies. Cases were compared against drug-tolerant controls.,HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with lamotrigine.,*15:02:01
390,HLA_B_5801,lamotrigine (PA450164),Case report. A 32-year-old woman with epilepsy was prescribed lamotrigine. She then developed maculopapular drug eruption. Genotyping showed the presence of HLA-B*5801 and the absence of HLA-B*1502.,HLA-B *58:01 is associated with Drug Hypersensitivity when treated with lamotrigine in women with Epilepsy.,*58:01
391,HLA_B_5801,lamotrigine (PA450164),"Please note that this allele did not meet the adjusted significance threshold of 0.00016. The frequency of the HLA-B*58:01 allele was significantly higher in those with lamotrigine-induced severe cutaneous adverse reactions (SCARs), as compared to lamotrigine-tolerant controls or population controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*58:01
392,HLA_B_5701,lamotrigine (PA450164),"No significant difference in the frequency of the HLA-B*57:01 allele was seen between those with lamotrigine-induced severe cutaneous adverse reactions (SCARs) and lamotrigine-tolerant controls or population controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction.",HLA-B *57:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with lamotrigine.,*57:01:01
393,HLA_C_0718,lamotrigine (PA450164),"Please note that this allele did not meet the adjusted significance threshold of 0.00016. The frequency of the HLA-C*07:18 allele was significantly higher in those with lamotrigine-induced severe cutaneous adverse reactions (SCARs), as compared to lamotrigine-tolerant controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction. Note that this allele was found to be strongly correlated with HLA-B*58:01.",HLA-C *07:18 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*07:18
394,HLA_DQB1_0609,lamotrigine (PA450164),"Please note that this allele did not meet the adjusted significance threshold of 0.00016. The frequency of the HLA-DQB1*06:09 allele was significantly higher in those with lamotrigine-induced severe cutaneous adverse reactions (SCARs), as compared to lamotrigine-tolerant controls or population controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction. Note that this allele was found to be strongly correlated with HLA-B*58:01.",HLA-DQB1 *06:09 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*06:09
395,HLA_DRB1_1301,lamotrigine (PA450164),"Please note that this allele did not meet the adjusted significance threshold of 0.00016. The frequency of the HLA-DRB1*13:01 allele was significantly higher in those with lamotrigine-induced severe cutaneous adverse reactions (SCARs), as compared to lamotrigine-tolerant controls. No significant results were seen when comparing against population controls. SCARs included Stevens-Johnson Syndrome, toxic epidermal necrolysis and hypersensitivity reaction.",HLA-DRB1 *13:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with lamotrigine.,*13:01:01
396,HLA_B_3801,clozapine (PA449061),"The presence of the HLA-B38 serotype was associated with an increased likelihood of experiencing clozapine-induced agranulocytosis. Note that this annotation was completed on HLA-B*38:01:01 because the B38 serotype recognizes HLA-B*38 alleles, and *38:01:01 was the first *38 allele discovered.",HLA-B *38:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*38:01:01
397,HLA_A_0201,"amoxicillin (PA448406),""ampicillin (PA448419)"",""bacampicillin (PA164745461)""","In patients who experienced delayed hypersensitivity to aminopenicillins, there was a higher prevalence of the HLA-A2 serotype, as compared to a random population sample. Note that this annotation was completed on HLA-A*02:01 because the A2 serotype recognizes HLA-A*02 alleles, and *02:01 was the first *02 allele discovered.","HLA-A *02:01 is associated with increased risk of Hypersensitivity, Delayed when treated with amoxicillin, ampicillin or bacampicillin.",*02:01
398,HLA_B_1502,oxcarbazepine (PA450732),Case report. A 53-year-old man with seizures who was given oxcarbazepine developed Stevens-Johnson Syndrome. Genotyping results showed presence of the HLA-B*1502 allele (genotype HLA-B*1502/HLA-B*46).,HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with oxcarbazepine in men with Seizures.,*15:02:01
399,HLA_B_1502,"carbamazepine (PA448785),""oxcarbazepine (PA450732)"",""phenobarbital (PA450911)"",""phenytoin (PA450947)""","Case report with two female Han Chinese patients. The first patient developed maculopapular rash after receiving carbamazepine and then again after receiving oxcarbazepine. No rash occurred after treatment with levetiracetam. The second patient developed Stevens-Johnson Syndrome after receiving phenytoin, then developed a maculopapular eruption after receiving phenobarbital and then again after receiving carbamazepine. No reaction occurred after treatment with topiramate. The authors state that this study reports cross-reactivity to these anti-epileptics.","HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.",*15:02:01
400,HLA_B_1301,dapsone (PA449211),Dapsone-induced hypersensitivity reaction (DIHR). HLA-B*13:01 was present at a significantly higher frequency in leprosy patients with DIHR as compared to dapsone-tolerant controls or healthy controls. Bonferroni-corrected p-values.,HLA-B *13:01:01 is associated with increased risk of Drug Hypersensitivity when treated with dapsone in people with Leprosy.,*13:01:01
401,HLA_C_0702,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0702.,HLA-C *07:02:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*07:02:01:01
402,HLA_DQA1_0201,"azathioprine (PA448515),""mercaptopurine (PA450379)""",Haplotype hla-DQA1*02:01-HLA-DRB1*07:01 was associated with risk.,HLA-DQA1 *02:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.,*02:01
403,HLA_DRB1_0701,"azathioprine (PA448515),""mercaptopurine (PA450379)""",Haplotype hla-DQA1*02:01-HLA-DRB1*07:01 was associated with risk.,HLA-DRB1 *07:01:01:01 is associated with increased risk of Pancreatitis when treated with azathioprine or mercaptopurine in people with Inflammatory Bowel Diseases.,*07:01:01:01
404,HLA_B_3501,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 3501.,HLA-B *35:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*35:01:01:01
405,HLA_B_3802,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 3802.,HLA-B *38:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*38:02:01
406,HLA_B_3901,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 3901.,HLA-B *39:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*39:01:01:01
407,HLA_B_4001,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 4001.,HLA-B *40:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*40:01:01
408,HLA_C_0801,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0801.,HLA-C *08:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*08:01:01
409,HLA_C_0803,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 0803.,HLA-C *08:03:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*08:03:01
410,HLA_C_1202,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 1202.,HLA-C *12:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*12:02:01
411,HLA_C_1402,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 1402.,HLA-C *14:02:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*14:02:01
412,HLA_C_1403,allopurinol (PA448320),P-values <5.62E-8 were considered statistically significant. Allele described as 1403.,HLA-C *14:03 is not associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*14:03
413,HLA_DQB1_0502,clozapine (PA449061),"The HLA-DQB1*05:02 allele was more frequent in those with clozapine-induced agranulocytosis, as compared to clozapine-tolerant controls. No adjustment for multiple comparisons made.",HLA-DQB1 *05:02:01 is associated with increased risk of Agranulocytosis when exposed to clozapine in people with Schizophrenia.,*05:02:01
414,HLA_DQB1_0201,clozapine (PA449061),"Trend for association. The HLA-DQB1*02:01 allele was more frequent in those with clozapine-induced agranulocytosis, as compared to clozapine-tolerant controls. No adjustment for multiple comparisons made.",HLA-DQB1 *02:01:01 is associated with increased risk of Agranulocytosis when exposed to clozapine in people with Schizophrenia.,*02:01:01
415,HLA_D_B502,clozapine (PA449061),"The HLA-DRB5*02 allele group was more frequent in those with clozapine-induced agranulocytosis, as compared to clozapine-tolerant controls. No adjustment for multiple comparisons made. Note that this annotation is on DRB5*02:02 because this was the first DRB5*02 allele discovered.",HLA-DRB5 *02:02 is associated with increased risk of Agranulocytosis when exposed to clozapine in people with Schizophrenia.,*02:02
416,HLA_DQB1_0602,"amoxicillin (PA448406),""clavulanate (PA164742987)""","There was a higher frequency of the HLA-DQB1*0602 allele in patients with amoxicillin-clavulanate-induced hepatitis, as compared to healthy controls. Additionally, the haplotype DRB1*1501-DRB5*0101-DQB1*0602 was also more frequent in those with amoxicillin-clavulanate-induced hepatitis. The haplotype was also present in those with extrahepatic manifestations (interstitial nephritis, skin rash, skin rash and arthritis, eosinophila; not statistically analyzed).",HLA-DQB1 *06:02:01 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.,*06:02:01
417,HLA_DRB1_1501,"amoxicillin (PA448406),""clavulanate (PA164742987)""","There was a higher frequency of the HLA-DRB1*1501 allele in patients with amoxicillin-clavulanate-induced hepatitis, as compared to healthy controls. Additionally, the haplotype DRB1*1501-DRB5*0101-DQB1*0602 was also more frequent in those with amoxicillin-clavulanate-induced hepatitis. The haplotype was also present in those with extrahepatic manifestations (interstitial nephritis, skin rash, skin rash and arthritis, eosinophila; not statistically analyzed).",HLA-DRB1 *15:01:01:01 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.,*15:01:01:01
418,HLA_D_B501,"amoxicillin (PA448406),""clavulanate (PA164742987)""","There was a higher frequency of the HLA-DRB5*0101 allele in patients with amoxicillin-clavulanate-induced hepatitis, as compared to healthy controls. Additionally, the haplotype DRB1*1501-DRB5*0101-DQB1*0602 was also more frequent in those with amoxicillin-clavulanate-induced hepatitis. The haplotype was also present in those with extrahepatic manifestations (interstitial nephritis, skin rash, skin rash and arthritis, eosinophila; not statistically analyzed).",HLA-DRB5 *01:01:01 is associated with increased risk of Hepatitis when treated with amoxicillin and clavulanate in people with Infection.,*01:01:01
419,HLA_B_1301,phenytoin (PA450947),"No significant difference in the frequency of the HLA-B*13:01 allele was seen between phenytoin-tolerant controls and patients with severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS). Additionally, no significant results were seen when considering SJS/TEN or DRESS individually. Note that p-values were corrected using Bonferroni's correction.",HLA-B *13:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.,*13:01:01
420,HLA_B_5101,phenytoin (PA450947),"No significant difference in the frequency of the HLA-B*51:01 allele was seen between phenytoin-tolerant controls and patients with severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS). Additionally, no significant results were seen when considering SJS/TEN or DRESS individually. Note that p-values were corrected using Bonferroni's correction.",HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.,*51:01:01
421,HLA_B_1502,phenytoin (PA450947),"The HLA-B*15:02 allele was more frequent in patients who developed phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to phenytoin-tolerant controls. However, no significant results were seen when considering drug reactions with eosinophilia and systemic symptoms (DRESS) or severe cutaneous adverse reactions (SCARs - both SJS/TEN and DRESS). Note that p-values were corrected using Bonferroni's correction.","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:02:01
422,HLA_B_1502,carbamazepine (PA448785),"32/35 (91.4%) of those with Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS/TEN overlap carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics.","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.",*15:02:01
423,HLA_B_1502,carbamazepine (PA448785),"2/3 (66.7%) of those with drug reaction with eosinophilia and systemic symptoms (DRESS) carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics.",HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.,*15:02:01
424,HLA_B_1502,carbamazepine (PA448785),"34/38 (89.5%) of those with severe cutaneous adverse reactions (Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), SJS/TEN overlap, drug reaction with eosinophilia and systemic symptoms (DRESS)) carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics. The authors note that 3 patients had a history of prior rashes induced by phenytoin and phenobarbital in a total of 4 exposures.",HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*15:02:01
425,HLA_B_4601,carbamazepine (PA448785),"5/38 (13.2%) of those with severe cutaneous adverse reactions (Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), SJS/TEN overlap, drug reaction with eosinophilia and systemic symptoms (DRESS)) carried the *15:02 allele, as compared to 9/25 (36%) of controls.",HLA-B *46:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.,*46:01:01
426,HLA_B_1402,nevirapine (PA450616),"When in a haplotype with HLA-C*08:02. 46% (6/13) of those with nevirapine hypersensitivity had the HLA-C*08:02 and HLA-B*14:02 antigens, compared with 5% (2/36) of the nevirapine-tolerant group. The HLA-C*8 and HLA-B*14 alleles are noted to be in linkage disequilibrium.",HLA-B *14:02:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*14:02:01
427,HLA_C_0802,nevirapine (PA450616),"When in a haplotype with HLA-B*14:02. 46% (6/13) of those with nevirapine hypersensitivity had the HLA-C*08:02 and HLA-B*14:02 antigens, compared with 5% (2/36) of the nevirapine-tolerant group. The HLA-C*8 and HLA-B*14 alleles are noted to be in linkage disequilibrium.",HLA-C *08:02:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*08:02:01
428,HLA_DQB1_0602,Influenza vaccines (PA164712830),"28 children had symptoms of narcolepsy that started after H1N1 vaccination (Pandemrix). All patients were positive for HLA-DQB1*06:02. The mean time between vaccination and development of symptoms was 9.5 weeks. The annual incidence of narcolepsy in children prior to the H1N1 vaccination was 0.26/100,000 and was 6.6/100,000 during the period after the vaccination. There were also 9 children who developed symptoms before the H1N1 vaccination; all but one of these children also had the HLA-DQB1*06:02 allele.",HLA-DQB1 *06:02:01 is associated with Narcolepsy when exposed to Influenza vaccines in children.,*06:02:01
429,HLA_DQB1_0602,Influenza vaccines (PA164712830),"24 narcolepsy cases were studied, 16 were diagnosed before receiving the H1N1 vaccine or were never vaccinated. The remaining 8 were vaccinated before onset of narcolepsy. The frequency of the *06:02 allele was similar between the groups (12/16 (75%) vs 7/8 (88%), respectively). The authors note that the allele was present in all 16 cases of narcolepsy accompanied by cataplexy, but only 3/8 cases without cataplexy.",HLA-DQB1 *06:02:01 is not associated with Narcolepsy when exposed to Influenza vaccines.,*06:02:01
430,HLA_C_0401,nevirapine (PA450616),"Please note the association is reported for HLA-C*04. Although there were differences between the different cutaneous manifestations of nevirapine hypersensitivity, mild and severe reactions were grouped together. The overall pooled effect was significant [OR 2.63 (95% CI: 1.97–3.52); I2=0%] with no heterogeneity between studies. Effect estimates were significant for black Africans [OR 3.36 (95% CI: 1.99–5.65); I2=14%], Caucasians [OR 1.92 (95% CI: 1.11–3.35)] and Thai [OR 2.56 (95% CI: 1.46–4.49); I2=0%], but not for North-East Asians [OR 2.92 (95% CI: 0.90–9.45)].",HLA-C *04:01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.,*04:01:01:01
431,HLA_B_5701,abacavir (PA448004),Meta-analysis with 10 studies. Abacavir hypersensitivity diagnosed by clinical evaluation with (n=5 studies) or without (n=5 studies) immunologic confirmation (skin patch test).,HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
432,HLA_B_5701,abacavir (PA448004),"Within the following subgroups: broad (standard) clinical diagnosis criteria, strict clinical diagnosis criteria, immunological criteria (patch test), Whites (clinical diagnosis criteria and immunological criteria), Africans and individuals of African descent (clinical diagnosis criteria and immunological criteria), Hispanics (clinical diagnosis criteria).",HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
433,HLA_B_5901,methazolamide (PA450413),Case study. A patient was diagnosed with toxic epidermal necrolysis following treatment with methazolamide. He was found to have the HLA-B*59:01:01:01 genotype.,"HLA-B *59:01:01:01 is associated with Epidermal Necrolysis, Toxic when treated with methazolamide in people with Glaucoma.",*59:01:01:01
434,HLA_B_5701,abacavir (PA448004),"The HLA-B*57:01 allele was present in 94.4% of cases of definite abacavir hypersensitivity compared with 1.7% of abacavir-tolerant controls. When in combination with the rs2227956 T allele (Hsp70-Hom M493T), the strength of the association increased, with this combination being present in 94.4% of cases of abacavir hypersensitivity, compared with 0.43% of controls.",HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
435,HLA_B_5701,abacavir (PA448004),"The HLA-B*57:01 allele was present in 42.3% of cases of abacavir hypersensitivity, as compared to 3.7% of abacavir-tolerant controls.",HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
436,HLA_B_1502,sulfamethoxazole and trimethoprim (PA10715),,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.",*15:02:01
437,HLA_C_0602,sulfamethoxazole and trimethoprim (PA10715),,"HLA-C *06:02:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.",*06:02:01:01
438,HLA_C_0801,sulfamethoxazole and trimethoprim (PA10715),,"HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with sulfamethoxazole and trimethoprim.",*08:01
439,HLA_DQB1_0602,Influenza vaccines (PA164712830),Case report. A 19-year-old woman developed symptoms of what was later diagnosed as narcolepsy starting 40 days after being vaccinated against the 2009 pandemic influenza A (H1N1) virus (Arepanrix). She was found to carry the HLA-DQB1*06:02 allele.,HLA-DQB1 *06:02:01 is associated with Narcolepsy when exposed to Influenza vaccines.,*06:02:01
440,HLA_DQB1_0602,Influenza vaccines (PA164712830),"14 cases of individuals who developed narcolepsy-cataplexy after receiving the H1N1 flu vaccine were identified. Individuals received either the H1N1 with adjuvant AS03 (Pandemrix n=7 or Arepranrix n=4) or H1N1 with no adjuvant (MedImmune-mist and Panenza n=1 or injectable n=1 or Panenza n=1). All patients had the HLA-DQB1*06:02 allele. Delay between the vaccination and narcolepsy onset ranged from 2 days to 5 months, though most occurred within 2-8 weeks.",HLA-DQB1 *06:02:01 is associated with Narcolepsy when treated with Influenza vaccines.,*06:02:01
441,HLA_B_3501,nevirapine (PA450616),"Please note the association is reported for HLA-B*35. The meta-analysis is based on studies with different populations. The association was largely driven by the Thai population, where the effect estimate was highly significant [OR 9.34 (95% CI: 2.68–32. 58)]. The pooled effect estimate was statistically significant [OR 2.45 (95% CI: 1.10–5.48)], although there was substantial heterogeneity amongst the populations (I2:69%).",HLA-B *35:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with nevirapine.,*35:01:01:01
442,HLA_B_5801,nevirapine (PA450616),There was a significant difference in the risk of hepatotoxicity in nevirapine-hypersensitive patients carrying the B*58:01 allele and there was no heterogeneity between the studies [OR 3.51 (95% CI: 1.72–7.19); I2=0%].,HLA-B *58:01 is associated with increased risk of Toxic liver disease when treated with nevirapine.,*58:01
443,HLA_B_1502,carbamazepine (PA448785),"The *15:02 was significantly associated with carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) in an individual analysis, as well as in a pooled-sample analysis and a meta-analysis of two studies. Patients were of Indian background, with those of non-Indian ancestry excluded from the study.","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.",*15:02:01
444,HLA_B_1502,carbamazepine (PA448785),The frequency of the *15:02 allele was higher in those with carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to carbamazepine-tolerant patients.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.",*15:02:01
445,HLA_B_1502,phenytoin (PA450947),The HLA-B*15:02 allele was not observed in those with phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) or phenytoin-tolerant controls.,"HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:02:01
446,HLA_DRB1_0101,nevirapine (PA450616),"The pooled effect estimate was significant [OR 3.70 (95% CI: 1.46–9.39); I2=52%], although there was substantial heterogeneity between studies. Exclusion of one study resulted in a reduction in heterogeneity and an increase in statistical significance (P<0.0001) with an OR of 3.02 (1.82–5.62).",HLA-DRB1 *01:01:01 is associated with increased risk of Hypersensitivity when treated with nevirapine.,*01:01:01
447,HLA_DRB1_0101,nevirapine (PA450616),"Please note the associations was reported for HLA-DRB1*01. Pooled effect estimate was significant OR 2.94 (95% CI: 1.92–4.0). For the black African [OR 2.14 (95% CI: 1.02–4.50) and White [OR 3.34 (95% CI: 1.97–5.66) subpopulations, the effect estimate was significant, but not for North-East Asians [OR 8.00 (95% CI: 0.49–131.37)],",HLA-DRB1 *01:01:01 is associated with increased risk of Toxic liver disease when treated with nevirapine.,*01:01:01
448,HLA_DRB1_0101,nevirapine (PA450616),"Controls were individuals who had received nevirapine for more than 6 weeks without symptoms, cases were those who developed nevirapine-induced hepatic/systemic reactions drug reactions. The presence of both more than 25% CD4 T cells and HLA-DRB1*0101 was associated with an increased risk for hepatic/systemic nevirapine reactions as compared to those without these factors. p-value listed below is after correction for multiple comparisons. Positive and negative predictive values were 40 and 96%, respectively. While HLA-DRB1*0101 was associated with an increased risk for hepatic/systemic reactions on its own (p=0.01, OR=4.8), this p-value was not significant after correction for multiple comparisons (p=0.14).",HLA-DRB1 *01:01:01 is associated with increased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*01:01:01
449,HLA_B_5801,allopurinol (PA448320),"87/92 of individuals with allopurinol-induced severe cutaneous adverse reactions (SCARs) carried the HLA-B*58:01 allele, as compared to 9/75 of allopurinol-tolerant patients and 10/99 of healthy volunteers. SCARs included drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). p-values were significant after correction for multiple testing. Note that frequencies of HLA-B*58:01 in different cohorts based on presence of the allele only.",HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.,*58:01
450,HLA_DRB1_0701,lapatinib (PA152241907),"HLA-DRB1*07:01 was associated with lapatinib-induced liver injury. The authors performed a genome-wide association study (GWAS) and a whole genome sequencing (WGS) study to reveal associations between genetic variants and lapatinib-induced liver injury. Participants in the study were from a clinical trial for lapatinib in women with breast cancer. The GWAS included 34 cases with baseline alanine aminotransferase (ALT) <= 1XULN (upper limit of normal) and max ALT > 3XULN, and 810 controls with baseline and all ALT <= 1xULN. The WGS study took a portion of patients from the study who had hepatologist adjucated, possible Hy's cases/extreme ALT cases (n=26) and 19 matched controls. HLA-DRB1*07:01 was the only significant finding from the GWAS. No individual variants showed a significant association for the WGS study, the authors suggest this is due to the small sample size.",HLA-DRB1 *07:01:01:01 is associated with increased risk of drug-induced liver injury when treated with lapatinib.,*07:01:01:01
451,HLA_A_0101,carbamazepine (PA448785),"The frequency of the HLA-A*01:01:01 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the general Mexican Mestizo population. Corrected p-value. Significant results were also see when compared against carbamazepine-tolerant controls (n=18), but only before correction of the p-value (p=0.028; OR=7.29 (1.02 - 52.01)).",HLA-A *01:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*01:01:01:01
452,HLA_A_3101,carbamazepine (PA448785),"Only BEFORE p-value correction. The frequency of the HLA-A*31:01:02 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the carbamazepine tolerant group and in the general Mexican Mestizo population. After p-value correction the p-values were 0.0619 and 0.1773, respectively, for these associations.",HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*31:01:02
453,HLA_A_2301,lamotrigine (PA450164),Only BEFORE p-value correction. The frequency of the HLA-A*23:01:01 allele in the lamotrigine-induced Stevens-Johnson Syndrome group was higher than that in the lamotrigine tolerant group. After p-value correction the p-value was 0.2531 for this association.,HLA-A *23:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine.,*23:01:01
454,HLA_B_4002,lamotrigine (PA450164),"Only BEFORE p-value correction. The frequency of the HLA-B*40:02:01 allele in the lamotrigine-induced Stevens-Johnson Syndrome group was higher than that in the lamotrigine tolerant group and in the general Mexican Mestizo population. After p-value correction the p-values were 0.1184 and 0.1323, respectively, for these associations.",HLA-B *40:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine.,*40:02:01
455,HLA_B_3501,carbamazepine (PA448785),Only BEFORE p-value correction. The frequency of the HLA-A*35:01:01 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the carbamazepine tolerant group. After p-value correction the p-value was 0.0537 for this association.,HLA-B *35:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.,*35:01:01:01
456,HLA_B_5701,lamotrigine (PA450164),"Only BEFORE p-value correction. The frequency of the HLA-B*57:01:01 allele in the lamotrigine-induced Stevens-Johnson Syndrome group was higher than that in the lamotrigine tolerant group and in the general Mexican Mestizo population. After p-value correction the p-values were 0.2531 and 0.2721, respectively, for these associations.",HLA-B *57:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine.,*57:01:01
457,HLA_B_5801,lamotrigine (PA450164),"Only BEFORE p-value correction. The frequency of the HLA-B*58:01:01 allele in the lamotrigine-induced Stevens-Johnson Syndrome group was higher than that in the lamotrigine tolerant group and in the general Mexican Mestizo population. After p-value correction the p-values were 0.2531 and 0.0992, respectively, for these associations.",HLA-B *58:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with lamotrigine.,*58:01
458,HLA_C_0801,phenytoin (PA450947),The frequency of the HLA-C*08:01 allele in the phenytoin-induced maculopapular exanthema group was higher than that in the phenytoin tolerant group and in the general Mexican Mestizo population. Corrected p-values.,HLA-C *08:01 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.,*08:01
459,HLA_B_1502,lamotrigine (PA450164),Meta-analysis with 4 studies. The frequency of the *15:02 allele was higher in those with lamotrigine-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) as compared to lamotrigine-tolerant controls.,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.",*15:02:01
460,HLA_A_3002,"amoxicillin (PA448406),""clavulanate (PA164742987)""","The frequency of the *30:02 allele was 1) higher in cases of amoxicillin-clavulanate drug-induced liver injury (DILI), hepatocellular type of damage, as compared to controls and 2) higher in Hy's law cases as compared to controls. Additionally, the frequency of the haplotype HLA-A*30:02-B*18:01 was higher in cases of DILI, hepatocellular type of damage, as compared to controls. Controls were taken from the general population, and had no known history of DILI (it is assumed that a large proportion of these controls would have taken amoxicillin-clavulanate at some point in their lives). p-value corrected for multiple comparisons.",HLA-A *30:02:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*30:02:01
461,HLA_B_1801,"amoxicillin (PA448406),""clavulanate (PA164742987)""","The frequency of the *18:01 allele was higher in cases of amoxicillin-clavulanate drug-induced liver injury (DILI), hepatocellular type of damage, as compared to controls (p=0.0082), though this result was no longer significant after correction for multiple comparisons. However, the haplotype HLA-A*30:02-B*18:01 was more common in DILI cases (hepatocellular type of damage) as compared to controls, even after correction for multiple comparisons. Controls were taken from the general population, and had no known history of DILI (it is assumed that a large proportion of these controls would have taken amoxicillin-clavulanate at some point in their lives).",HLA-B *18:01:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*18:01:01
462,HLA_DQB1_0602,"amoxicillin (PA448406),""clavulanate (PA164742987)""","The frequency of the *06:02 allele was higher in cases of amoxicillin-clavulanate drug-induced liver injury (DILI), cholestatic/mixed type of damage, as compared to controls. Controls were taken from the general population, and had no known history of DILI (it is assumed that a large proportion of these controls would have taken amoxicillin-clavulanate at some point in their lives). The haplotype HLA-DRB1*15:01-DQB1*06:02 was also more common in DILI cases (cholestatic/mixed type of damage) as compared to controls. p-values corrected for multiple comparisons.",HLA-DQB1 *06:02:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*06:02:01
463,HLA_DRB1_1501,"amoxicillin (PA448406),""clavulanate (PA164742987)""","The frequency of the *15:01 allele was higher in cases of amoxicillin-clavulanate drug-induced liver injury (DILI), cholestatic/mixed type of damage, as compared to controls (p=0.0024), though this result was no longer significant after correction for multiple comparisons. However, the haplotype HLA-DRB1*15:01-DQB1*06:02 was more common in DILI cases (cholestatic/mixed type of damage) as compared to controls, even after correction for multiple comparisons. Controls were taken from the general population, and had no known history of DILI (it is assumed that a large proportion of these controls would have taken amoxicillin-clavulanate at some point in their lives).",HLA-DRB1 *15:01:01:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*15:01:01:01
464,HLA_B_3505,"lamivudine (PA450163),""nevirapine (PA450616)"",""stavudine (PA451494)""","HLA-B*35:05 was a significant predictor of regimen modification due to rash, with presence of the *35:05 allele leading to an increased risk for regimen modification due to rash. This allele was the strongest predictor of regimen modification due to rash.","HLA-B *35:05:01 is associated with Exanthema when treated with lamivudine, nevirapine and stavudine in people with HIV.",*35:05:01
465,HLA_B_3901,sulfasalazine (PA451547),Allele described as *39:01.,HLA-B *39:01:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.,*39:01:01:01
466,HLA_B_1301,sulfasalazine (PA451547),"Allele described as *13:01 in the comparison with healthy controls, and *13:01:01 in the comparison with tolerant controls.",HLA-B *13:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.,*13:01:01
467,HLA_B_1505,sulfasalazine (PA451547),"Allele described as *15:05 in the comparison against healthy control, and *15:05:01 in the comparison against tolerant controls. This association was only significant vs healthy controls and not vs tolerant controls.",HLA-B *15:05:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with sulfasalazine.,*15:05:01
468,HLA_DQB1_0402,bucillamine (PA166123566),"The HLA-DQB1*04:02 allele was more frequent in patients with bucillamine-induced proteinuria, as compared to bucillamine-tolerant patients (p-value corrected for multiple comparisons). The *04:02 allele was in linkage disequilibrium with HLA-DRB1*08:02 (D'=0.625, r2=0.192), and the haplotype DRB1*08:02-DQB1*04:02 was also associated with bucillamine-induced proteinuria.","HLA-DQB1 *04:02:01 is associated with increased risk of Proteinuria when treated with bucillamine in people with Arthritis, Rheumatoid.",*04:02:01
469,HLA_DRB1_0802,bucillamine (PA166123566),"The HLA-DRB1*08:02 allele was more frequent in patients with bucillamine-induced proteinuria, as compared to bucillamine-tolerant patients (p-value corrected for multiple comparisons). The *08:02 allele was in linkage disequilibrium with HLA-DQB1*04:02 (D'=0.625, r2=0.192), and the haplotype DRB1*08:02-DQB1*04:02 was also associated with bucillamine-induced proteinuria.","HLA-DRB1 *08:02:01 is associated with increased risk of Proteinuria when treated with bucillamine in people with Arthritis, Rheumatoid.",*08:02:01
470,HLA_B_5901,methazolamide (PA450413),"Cases had methazolamide-induced Stevens-Johnson Syndrome (SJS; n=2) or toxic epidermal necrolysis (TEN; n=6), controls were either methazolamide-tolerant individuals (n=30) or healthy Chinese subjects from the human major histocompatibility complex database (n=283). Cases had received methazolamide for treatment of post-operative intraocular pressure elevation and glaucoma; all tolerant controls had received methazolamide for glaucoma.","HLA-B *59:01:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.",*59:01:01:01
471,HLA_C_0102,methazolamide (PA450413),"Cases had methazolamide-induced Stevens-Johnson Syndrome (SJS; n=2) or toxic epidermal necrolysis (TEN; n=6), controls were either methazolamide-tolerant individuals (n=30) or healthy Chinese subjects from the human major histocompatibility complex database (n=283). Cases had received methazolamide for treatment of post-operative intraocular pressure elevation and glaucoma; all tolerant controls had received methazolamide for glaucoma.","HLA-C *01:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with methazolamide.",*01:02:01
472,HLA_A_3101,carbamazepine (PA448785),Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-A*31 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*31:01:02 because this was the first *31 allele discovered. The authors also note that the HLA-A*31 allele does not determine carbamazepine-induced lymphocyte proliferation.,HLA-A *31:01:02 is associated with increased risk of Drug Toxicity when treated with carbamazepine.,*31:01:02
473,HLA_A_1101,carbamazepine (PA448785),"Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-A*11 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*11:01:01 because this was the first *11 allele discovered. The authors note that though the p-value was non-significant, they considered this result significant because the 95% confidence interval (CI) of the odds ratio (OR) did not cross 1 (95% CI = 1.009 - 24.773).",HLA-A *11:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.,*11:01:01
474,HLA_A_0201,carbamazepine (PA448785),Patients with carbamazepine-induced adverse drug reactions had a lower frequency of the HLA-A*02 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*02:01 because this was the first *02 allele discovered.,HLA-A *02:01 is associated with decreased risk of Drug Toxicity when treated with carbamazepine.,*02:01
475,HLA_B_5101,carbamazepine (PA448785),Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-B*51:01 allele as compared to carbamazepine-tolerant patients.,HLA-B *51:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.,*51:01:01
476,HLA_DRB1_0701,asparaginase (PA448492),"The authors used a discovery and validation cohort to test the association between asparaginase hypersensitivity and HLA alleles. Multivariate analysis showed that sex, ALL immunophenotype, and treatment protocol (including whether asparaginase was native ""E. coli"" or pegylated ""E. coli"" asparaginase) were associated with asparaginase hypersensitivity. There was a higher risk of hypersensitivity among B-lineage leukemia patients compared with T-lineage leukemia patients. Asparaginase hypersensitivities to native or PEGylated ""E. coli"" asparaginase were graded according to the National Cancer Institute common toxicity criteria; grade 2 and higher was considered as an allergy. Note: the authors also investigated asparaginase hypersensitivity that was dependent on specific amino acid substitutions within the HLA-DRB1*07:01 allele (""To determine the protein sequence features of HLA-DRB1*07:01 that confer a greater risk of asparaginase hypersensitivity, polymorphic amino acid variants of the HLA-DRB1 protein were inferred""). This is not reported here.",HLA-DRB1 *07:01:01:01 is associated with increased likelihood of Hypersensitivity when exposed to asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,*07:01:01:01
477,HLA_DQB1_0602,nevirapine (PA450616),"The *06:02:01 allele was associated with a decreased risk for developing drug reaction with eosinophilia and systemic symptoms (DRESS, also known as hypersensitivity syndrome (HSS)) when receiving nevirapine, as compared against the baseline ""rare allele"" group.",HLA-DQB1 *06:02:01 is associated with decreased risk of drug reaction with eosinophilia and systemic symptoms when treated with nevirapine in people with HIV.,*06:02:01
478,HLA_DQB1_0602,nevirapine (PA450616),"The *06:02 allele was associated with a decreased risk for developing drug-induced liver injury (DILI) on nevirapine, when compared against the baseline ""rare allele"" group.",HLA-DQB1 *06:02:01 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV.,*06:02:01
479,HLA_DQB1_0603,nevirapine (PA450616),"The *06:03:01 allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *06:03:01 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*06:03:01
480,HLA_DQB1_0609,nevirapine (PA450616),"The *06:09 allele was associated with a decreased risk for developing hypersensitivity reactions on nevirapine, including Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN), drug-induced liver injury (DILI) or hypersensitivity syndrome (HSS), when compared against the baseline ""rare allele"" group.",HLA-DQB1 *06:09 is associated with decreased risk of Drug Hypersensitivity when treated with nevirapine in people with HIV.,*06:09
481,HLA_DRB1_1503,nevirapine (PA450616),"The *15:03 allele was associated with a decreased risk for developing drug-induced liver injury (DILI) when receiving nevirapine, as compared against the baseline ""rare allele"" group.",HLA-DRB1 *15:03:01:01 is associated with decreased risk of drug-induced liver injury when treated with nevirapine in people with HIV.,*15:03:01:01
482,HLA_DQA1_0201,lapatinib (PA152241907),"The HLA-DQA1*02:01 allele was more frequent in cases (one or more on-treatment ALT measurements of > 3x the upper limit of normal (ULN)) than controls (non-cases). This allele was highly correlated with HLA-DRB1*07:01, with the two variants in almost perfect linkage disequilibrium.",HLA-DQA1 *02:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.,*02:01
483,HLA_DRB1_0701,lapatinib (PA152241907),"The HLA-DRB1*07:01 allele was more frequent in cases (one or more on-treatment ALT measurements of > 3x the upper limit of normal (ULN)) than controls (non-cases). Significant results were also seen when considering cases as having ALT measurements > 5xULN and > 10xULN. This allele was highly correlated with HLA-DQA1*02:01, with the two variants in almost perfect linkage disequilibrium.",HLA-DRB1 *07:01:01:01 is associated with increased risk of Toxic liver disease when treated with lapatinib in women with Breast Neoplasms.,*07:01:01:01
484,HLA_B_5701,abacavir (PA448004),"31% of individuals with suspected abacavir hypersensitivity carried the HLA-B*57:01 allele, as compared with 1% of abacavir-tolerant controls. ""Suspected abacavir hypersensitivity"" included 27 patients with likely hypersensitivity, 43 with clinically unlikely hypersensitivity, and 61 with clinically uncertain hypersensitivity. Note that the carriage rate of HLA-B*57:01 was higher in those with likely hypersensitivity (78%) as compared with uncertain (30%) or unlikely (5%) hypersensitivity.",HLA-B *57:01:01 is associated with increased risk of Drug Hypersensitivity when treated with abacavir in people with HIV.,*57:01:01
485,HLA_B_5801,allopurinol (PA448320),"Three patients were diagnosed with Stevens-Johnson Syndrome (SJS), two patients with toxic epidermal necrolysis (TEN). The authors note that mild ocular involvement with only conjunctival hyperemia was present in all ten eyes. No patients developed severe chronic ocular complications. 4 out of the 5 patients were positive for HLA-B*58:01.","HLA-B *58:01 is associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.",*58:01
486,HLA_B_5901,clozapine (PA449061),"Clozapine-induced agranulocytosis (CIA; n=23) or granulocytopenia (CIG; n=29) (CIAG). Initial GWAS analysis gave rs1800625 as the top hit in the MHC region (p=3.46x10^-9, where genome-wide significance was p<5x10^-8). Classical HLA typing was then done to assess the association of alleles between those with CIAG and healthy subjects. To validate this association, an independent comparison was done in clozapine-tolerant individuals.",HLA-B *59:01:01:01 is associated with increased risk of Agranulocytosis when treated with clozapine in people with Schizophrenia.,*59:01:01:01
487,HLA_B_3802,"carbimazole (PA164742970),""methimazole (PA450422)"",""propylthiouracil (PA451156)""","Patients with thioamide-induced agranulocytosis vs thioamide-tolerant controls. Thioamides include carbimazole (n=9), methimazole (n=23) and propylthiouracil (n=9). Carbimazole is a prodrug that is converted to its active form, methimazole. Carrying both HLA-B*38:02 and HLA-DRB1*08:03 increases the odds ratio for agranulocytosis to 48.41 (3.32x10^-21, CI: 21.66-108.22).","HLA-B *38:02:01 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.",*38:02:01
488,HLA_DRB1_0803,"carbimazole (PA164742970),""methimazole (PA450422)"",""propylthiouracil (PA451156)""","Patients with thioamide-induced agranulocytosis vs thioamide-tolerant controls. Thioamides include carbimazole (n=9), methimazole (n=23) and propylthiouracil (n=9). Carbimazole is a prodrug that is converted to its active form, methimazole. Carrying both HLA-B*38:02 and HLA-DRB1*08:03 increases the odds ratio for agranulocytosis to 48.41 (3.32x10^-21, CI: 21.66-108.22).","HLA-DRB1 *08:03:02 is associated with increased risk of Agranulocytosis when treated with carbimazole, methimazole or propylthiouracil in people with Graves Disease.",*08:03:02
489,HLA_B_1502,phenytoin (PA450947),"Association is not significant using Fisher’s exact test comparing the positive alleles of SCARs patients with the tolerant controls or Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).",HLA-B *15:02:01 is not associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.,*15:02:01
490,HLA_B_5101,phenytoin (PA450947),"Association for HLA-B*51:01 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).",HLA-B *51:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.,*51:01:01
491,HLA_B_1513,phenytoin (PA450947),"The HLA-B*15:13 allele was significantly more frequent in patients with phenytoin-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) (SJS/TEN), as well as drug reaction with eosinophilia and systemic symptoms (DRESS), as compared to phenytoin-tolerant controls. It was also significantly more frequent when compared to population controls.","HLA-B *15:13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:13:01
492,HLA_B_1502,phenytoin (PA450947),"The HLA-B*15:02 allele was significantly more frequent in patients with phenytoin-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) (SJS/TEN; 61.5%), as compared to phenytoin-tolerant controls (21.9%).","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:02:01
493,HLA_DRB1_1501,"amoxicillin (PA448406),""clavulanate (PA164742987)""","Co-amoxiclav. The frequency of the HLA-DRB1*15:01 allele was significantly higher in patients who developed co-amoxiclav drug-induced liver injury (DILI) as compared to population controls. No significant result was seen when comparing against co-amoxiclav-tolerant controls (p=0.0655). The authors also pooled their results with results from two other studies (PMID 10535882, 11034591) and again found a significant association when comparing against population controls. 116 patients total with co-amoxiclav-induced DILI were compared against the 191 population controls from THIS study.",HLA-DRB1 *15:01:01:01 is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*15:01:01:01
494,HLA_DRB1_0701,"amoxicillin (PA448406),""clavulanate (PA164742987)""",Co-amoxiclav. The frequency of the HLA-DRB1*07 allele was significantly lower in patients who developed co-amoxiclav drug-induced liver injury (DILI) as compared to tolerant controls or population controls. Please note that this annotation was done on *07:01:01:01 as this was the first *07 allele discovered.,HLA-DRB1 *07:01:01:01 is associated with decreased risk of drug-induced liver injury when treated with amoxicillin and clavulanate.,*07:01:01:01
495,HLA_B_1502,phenytoin (PA450947),"However, p<0.001 was considered statistically significant after adjusting for multiple comparisons using Bonferroni correction. Using this criteria, this association is no longer significant. Controls were patients tolerant to phenytoin after taking it for at least 3 months without developing a skin rash.","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.",*15:02:01
496,HLA_B_1502,carbamazepine (PA448785),Case report. A 28-year-old Malaysian Australian man of Han Chinese descent developed toxic epidermal necrolysis 2 weeks after commencing carbamazepine treatment. He was subsequently found to have the HLA-B*15:02 allele.,"HLA-B *15:02:01 is associated with Epidermal Necrolysis, Toxic when treated with carbamazepine.",*15:02:01
497,HLA_B_5801,allopurinol (PA448320),,"HLA-B *58:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol.",*58:01
498,HLA_B_4403,lamotrigine (PA450164),"Authors state that HLA-B*44:03 ""may be associated with lamotrigine-induced SJS/TEN"" (SJS = Stevens-Johnson Syndrome, TEN = toxic epidermal necrolysis)","HLA-B *44:03:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine.",*44:03:01
499,HLA_B_5101,phenytoin (PA450947),"Association for HLA-B*51:01 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).","HLA-B *51:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*51:01:01
500,HLA_B_3802,phenytoin (PA450947),"Association for *38:02 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).","HLA-B *38:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*38:02:01
501,HLA_B_1502,phenytoin (PA450947),"Association is not significant using Fisher’s exact test comparing the positive alleles of SCARs patients with the tolerant controls or Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).","HLA-B *15:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*15:02:01
502,HLA_C_1402,phenytoin (PA450947),"Association with HLA-C*14:02 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).","HLA-C *14:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.",*14:02:01
503,HLA_B_5801,allopurinol (PA448320),Case report. A 40-year old Chinese man developed likely allopurinol-induced drug reaction with eosinophilia and systemic symptoms (DRESS). He was tested for HLA-B*58:01 which returned a positive result. He had to spend 25 days in the hospital.,HLA-B *58:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with allopurinol.,*58:01
504,HLA_DQB1_0501,Drugs For Treatment Of Tuberculosis (PA164712708),"The proportion of the HLA-DQB1 *05/*05 genotype (i.e. patients with the *05:01, *05:02 or *05:03 alleles) was higher in patients with antituberculosis drug-induced liver injury (ATLI) as compared to controls. Significant in multivariate conditional logistic regression, adjusted for usage of liver protective drugs and weight.",HLA-DQB1 *05:01:01:01 + *05:02:01 + *05:03:01:01 is associated with increased risk of drug-induced liver injury when treated with Drugs For Treatment Of Tuberculosis in people with Tuberculosis.,*05:01:01:01 + *05:02:01 + *05:03:01:01
505,HLA_B_1502,"lamotrigine (PA450164),""valproic acid (PA451846)""",Controls were patients tolerant to lamotrigine or valproic acid after taking them for at least 3 months without developing a skin rash.,"HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with lamotrigine or valproic acid in people with Epilepsy.",*15:02:01
506,HLA_B_1502,antiepileptics (PA143485705),"Antiepileptics included carbamazepine (n=27), phenytoin (n=15), valproate (n=3), phenobarbital (n=2), lamotrigine (n=6), gabapentin (n=1) and levetiracertam (n=1). Controls were patients tolerant to antiepileptics after taking them for at least 3 months without developing a skin rash.","HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with antiepileptics in people with Epilepsy.",*15:02:01
507,HLA_B_3802,"carbimazole (PA164742970),""methimazole (PA450422)""","Patients with carbimazole (CMZ) or methimazole (MMI)-induced agranulocytosis vs CMZ/MMI-tolerant controls. CMZ is a pro-drug that is converted into its active form, MMI. The positive and negative predictive values of HLA-B*38:02:01 in predicting carbimazole/methimazole-induced agranulocytosis were 0.07 and 0.999 respectively. Approximately 211 cases would need to be screened to prevent one case.",HLA-B *38:02:01 is associated with increased risk of Agranulocytosis when treated with carbimazole or methimazole in people with Graves Disease.,*38:02:01
508,HLA_B_3802,propylthiouracil (PA451156),No patients with propylthiouracil-induced agranulocytosis or propylthiouracil-tolerant controls carried HLA-B*38:02:01.,HLA-B *38:02:01 is not associated with risk of Agranulocytosis when treated with propylthiouracil in people with Graves Disease.,*38:02:01
509,HLA_B_5602,phenytoin (PA450947),"Association is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).","HLA-B *56:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.",*56:02
510,HLA_DRB1_1601,flupirtine (PA166152829),"No genome-wide significant signal for flupirtine cases was detected in the GWAS but significant enrichment of the HLA-DRB1*16:01-DQB1*05:02 haplotype compared with the controls (minor allele frequency cases 0.25 and minor allele frequency controls 0.013; P=1.4×10-5) is found. The odds ratio for haplotype carriers was estimated of 18.7 (95% confidence interval 2.5-140.5, P=0.002) using population-specific HLA control data The association is reported for the DRB1*16:01-DQB1*05:02 haplotype (not single gene) carriage vs non-carriage. This findings were confirmed in the replication cohort including 6 original and 4 additional flupirtine cases. The discovery cohort for the GWAS were 5 case with confirmed flupirtine-induced liver injury and 1 ambiguous case in addition to 614 DILI patients that related to other drugs. The controls were matched to a range from Northern and Southern Europe.",HLA-DRB1 *16:01:01 is associated with increased risk of drug-induced liver injury when treated with flupirtine.,*16:01:01
511,HLA_B_1502,carbamazepine (PA448785),,"HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.",*15:02:01
512,HLA_B_1502,carbamazepine (PA448785),Case report. A 47-year-old woman of Asian decent. She had been on carbamazepine 300 mg twice daily for one month. HLA genetic testing revealed that the patient was HLA-B*15:02 positive. She was negative for HLA-A*31:01.,HLA-B *15:02:01 is associated with risk of Stevens-Johnson Syndrome when treated with carbamazepine in women with Epilepsy.,*15:02:01
513,HLA_DQB1_0502,flupirtine (PA166152829),"No genome-wide significant signal for flupirtine cases was detected in the GWAS but significant enrichment of the HLA-DRB1*16:01-DQB1*05:02 haplotype compared with the controls (minor allele frequency cases 0.25 and minor allele frequency controls 0.013; P=1.4×10-5) is found. The odds ratio for haplotype carriers was estimated of 18.7 (95% confidence interval 2.5-140.5, P=0.002) using population-specific HLA control data The association is reported for the DRB1*16:01-DQB1*05:02 haplotype (not single gene) carriage vs non-carriage. This findings were confirmed in the replication cohort including 6 original and 4 additional flupirtine cases. The discovery cohort for the GWAS were 5 case with confirmed flupirtine-induced liver injury and 1 ambiguous case in addition to 614 DILI patients that related to other drugs. The controls were matched to a range from Northern and Southern Europe.",HLA-DQB1 *05:02:01 is associated with increased risk of drug-induced liver injury when treated with flupirtine.,*05:02:01
514,HLA_B_1502,carbamazepine (PA448785),"Case report. A 16-year-old Spanish Romani patient developed Stevens-Johnson syndrome upon treatment with carbamazepine. HLA typing showed the HLA-B*15:02 allele. A lymphocyte transformation test (LTT) gave positive results for carbamazepine, lamotrigine and phenytoin. The authors estimate an HLA-B*15:02 phenotype frequency of 2% in this ethnic group, and note that HLA-B testing might be useful in this population. The LTT results suggest cross reactivity between carbamazepine and other aromatic antiepileptic drugs.",HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine in children with schizencephaly.,*15:02:01
